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Abstract	
TCR signal strength is critical for CD8+ T cell clonal expansion after antigen 
stimulation. Levels of the transcription factor IRF4 control the magnitude of this 
process through induction of genes involved in proliferation and glycolytic 
metabolism. The signaling mechanism connecting graded TCR signaling to the 
generation of varying amounts of IRF4 is not well understood. Here, using 
multiple methods to vary TCR signal strength and measure changes in 
transcriptional activation in single CD8+ T cells, we connect antigen potency to 
the kinetics of NFAT activation and Irf4 mRNA expression. T cells that transduce 
weaker TCR signals exhibit a marked delay in Irf4 mRNA induction resulting in 
decreased overall IRF4 expression in individual cells and increased 
heterogeneity within the clonal population. The activity of the tyrosine kinase ITK 
acts as a signaling catalyst that accelerates the rate of the cellular response to 
TCR stimulation, controlling the time to onset of Irf4 gene transcription. These 
findings provide insight into the signal transduction pathway accounting for the 
reduced clonal expansion of low affinity CD8+ T cells following infection. We also 
describe another context for ITK activity, autoreactive T cell migration. Here, we 
connect TCR signaling strength to modulation of selectin binding and 
autoreactive T cell-mediated pathology in an adoptive transfer model system of 
autoimmune disease. Understanding the signaling mechanisms linking changes 
in TCR signaling to CD8 T cell function is important in furthering the 
understanding of vaccine development and T cell adoptive immunotherapy. 
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The adaptive immune system involves highly differentiated cells 
cooperating for an organism to recognize “self” from “non-self,” thus providing a 
defense against invading pathogens while maintaining homeostasis within the 
organism. A central process in adaptive immunity is the generation of memory 
where cells specific for a particular antigen are able to mount a more effective 
response upon re-encounter. Here, we focus on one cell type critical in this whole 
process, the CD8+ T cell. These cells exit the thymus expressing the CD8 co-
receptor and are associated with cytotoxic functions, explaining their alterative 
name, cytotoxic T cells (Butz and Bevan, 1998). However, this name is too 
general in that CD4+ T cells are also able to perform cytotoxic functions (Marshall 
and Swain, 2011). We focus on these cells ability to recognize antigen and signal 
through multiple pathways to change their transcriptome, leading to robust clonal 
expansion and migration which are critical for an effective T cell-mediated 
immune response.  
T cells bind antigen through their T cell receptor (TCR), activating a 
signaling cascade that leads to proliferation, differentiation, and pathogen 
clearance (Weiss, 2005). The affinity of a T cell receptor for its cognate antigen 
has been directly linked to the regulation of thymic selection and the T cell 
immune response (Wherry et al., 1999). Upon receptor activation, tyrosine 
kinases are phosphorylated, creating signaling complexes at the plasma 
membrane that activate downstream signal transduction pathways. In response 
to activation, the T cell reorganizes its cytoskeleton, changes its metabolism, and 
alters its gene expression. This thesis focuses on the signaling pathways that 
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contribute to changes in gene expression. The three principal pathways activated 
through the TCR that control transcription are the MAPK, NF-κB, and calcium 
pathways. These pathways dramatically alter the expression and nuclear 
localization of various transcription factors that directly regulate genes involved in 
T cell activation (Brownlie and Zamoyska, 2013). 
T cells recognize peptide antigens displayed by the major 
histocompatibility complex (pMHC) on antigen presenting cells (APC). The 
interactions between the TCR and pMHC have been extensively characterized in 
the context of thymic selection and in the immune response to infection (Klein et 
al., 2014). In response to viral infection, CD8+ T cells recognize antigen from 
APCs in the lymphoid organs, undergo clonal expansion, migrate to the site of 
infection, kill infected cells, and then die by apoptosis. Some of the CD8+ T cells 
will survive this population contraction to form a memory pool (N. Zhang and 
Bevan, 2011). 
Because T cells are polyclonal and contain variable TCRs, they are able 
to recognize a wide variety of peptide ligands. These ligands can have variable 
binding affinities for the TCR, creating a range of ligand binding kinetics 
(Nikolich-Žugich et al., 2004). This variability contributes to the process of graded 
TCR signaling, where altered peptide ligands can generate different signaling 
outcomes depending on the binding kinetics of the TCR and pMHC. This 
introduction chapter highlights recent advances in the field which connect 
proximal TCR signaling and transcription factor activation to changes in CD8+ T 
cell function. We then highlight key questions regarding the control of TCR signal 
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strength on these functions and provide rationale for our studies examining this 
relationship.  
Graded	TCR	Stimulation	and	Signal	Transduction	
The effect of altered peptide ligands (APLs) on the proximal signaling 
events downstream of the TCR has been extensively examined. In the basal 
state, the ITAMs of the TCRζ chains are phosphorylated and bound to inactive 
Zap70. The dwell time of an agonist peptide interaction with the TCR is 
significantly longer than self-peptide interactions, creating a higher probability 
that a CD8 co-receptor bound to active Lck can be recruited and bind pMHC. 
This interaction is highly dependent on peptide sequence, the main factor driving 
interaction between pMHC and the TCR (Turner et al., 2006). Lck is normally 
inhibited by an intramolecular interaction between its SH2 domain and a Y505 
residue in the C-terminal tail (Sicheri et al., 1997; Xu et al., 1997). This regulatory 
tyrosine is controlled by CSK phosphorylation and CD45 dephosphorylation (Y. 
X. Tan et al., 2014). Autophosphorylation of Y394 allows for the open 
conformation of Lck to interact with the TCR (Hardwick and Sefton, 1995). This 
interaction increases complex stability and creates an opportunity for Lck to 
activate Zap70 by first phosphorylating Y319, relieving the autoinhibited 
conformation. Further activation of other tyrosine residues increases Lck and 
Zap70 kinase activity and further initiates both kinases to create the downstream 
LAT signaling complex (W. Zhang et al., 1998) (Chakraborty and Weiss, 2014). 
These proximal signaling events are absolutely required for downstream TCR 
signal transduction (Abraham and Weiss, 2004; Au-Yeung et al., 2009). Using an 
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engineered mutant allele of Zap70, which is sensitive to a small molecule kinase 
inhibitor, a sharp threshold of signaling was observed downstream of the kinase. 
Using Nur77-GFP as a readout for TCR signaling, Zap70 was determined to be 
required for signaling and cell division. This requirement was independent of both 
the strength of the pMHC-TCR interaction and IL-2 (Au-Yeung et al., 2014).  
Not all pathways downstream of the TCR are similarly affected by antigen 
avidity. The calcium signaling pathway has been shown to be disproportionately 
affected by weak antigen stimulation (J. L. Chen et al., 2010; Miller et al., 2004; 
Wülfing et al., 1997). The MAPK and NF-κB pathways, while activated by the 
TCR, have a threshold level of activation that is less affected by weak stimuli. 
The MAPK pathway starts with Ras activation and subsequently leads to 
downstream Erk activation and the formation of the transcription factor dimer AP-
1. In T cells, Ras is activated downstream of the TCR by RasGRP or SOS. 
Initially, RasGRP is activated by binding diacylglycerol (DAG), a byproduct of 
PtdIns(4,5)P2 (PIP2) cleavage, followed by phosphorylation by protein kinase c 
(PKC) at the plasma membrane. This process is dependent on TCR signal 
transduction and ultimately, on activation of phospholipase c (PLCγ). PLCγ 
activation gradually increases the local concentration of RasGRP at the LAT 
signaling complex. While this initial signaling event is graded in nature, it rapidly 
triggers a positive feedback loop. SOS acts as the integration point in this 
feedback loop; not only is it activated like RasGRP and recruited to the signaling 
complex, it has an allosteric binding site for RasGTP which substantially 
increases its GTPase activity (Das et al., 2009). This feedback loop ensures that 
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low affinity TCR ligation can trigger robust Ras activation. Many signaling outputs 
are often described as “digital” or “analog,” with a non-linear relationship 
observed between signaling input and output in the context of digital signaling 
and a linear response observed in the context of analog signaling. Indeed, a 
digital signal response is observed with p-Erk, with different affinity antigens 
triggering maximal pathway activation. CD69 was also observed to have this 
digital response and its expression was highly dependent on the MAPK pathway 
(Altan-Bonnet and Germain, 2005; Balyan et al., 2017; Das et al., 2009). 
A similar signaling effect was observed in the NF-κB pathway. Jurkat cells 
stimulated with different concentrations of αCD3 antibody were able to activate T 
cells in a graded manner. However, looking at IκBα degradation, the pathway 
was digital in nature with cells forming a bimodal population (Kingeter et al., 
2010). Using a mutant form of the OT-I TCR (bTMD) having intact antigen 
binding capacity but dampened signaling, a defect in PKC recruitment to the 
immunosynapse was observed shortly after stimulation. This defect lead to 
impaired CD8+ T cell memory formation. However, only a signaling defect in the 
NF-κB pathway was observed downstream of the TCR suggesting that a small 
signaling defect in this pathway could impair CD8+ T cell differentiation (Teixeiro 
et al., 2009). The diverse functions of NF-κB signaling downstream of the TCR 
have been extensively reviewed (Paul and Schaefer, 2013). 
The quality of the calcium signaling response is highly sensitive to TCR 
antigen affinity. Specifically, the influx oscillation patterns: time of onset, 
amplitude of influx, and frequency of influx of this cation are highly mutable (J. L. 
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Chen et al., 2010; Christo et al., 2015; Rosette et al., 2001; Wülfing et al., 1997). 
Using calcium indicator dyes to measure changes in intracellular ion 
concentration, changes in both the amplitude and duration of calcium influx have 
been observed upon stimulation with antigens of different affinities (J. L. Chen et 
al., 2010; Rosette et al., 2001). Low affinity pMHC does not trigger robust 
calcium influx in multiple in vitro T cell experiments. This has been linked to the 
regulation of calcium egress from the endoplasmic reticulum, a process that is 
mediated by the inositol trisphosphate receptor (IP3R) (J. L. Chen et al., 2010). 
In CD4+ T cells, the time of onset for calcium flux was directly proportional to the 
affinity of the antigen. Weaker pMHC stimulation also reduced the magnitude of 
the influx peak and the duration of the influx (Wülfing et al., 1997). Calcium 
oscillation patterns have been directly linked to nuclear signaling in T cells with a 
nonlinear relationship between [Ca2+] and transcription factor activation observed 
(Dolmetsch et al., 1998). Specifically, high frequency oscillation drove both NFAT 
and NF-κB activation, while low frequency oscillation drove only NF-κB 
activation. This, combined with differences in nuclear dwell time (>15m for NF-kB 
and <10m for NFAT), accounts for variable pathway activation in response to 
changes in calcium influx (Dolmetsch et al., 1997).  
The calcium-sensitive transcription factor NFAT is well known for its 
contribution to T cell activation, specifically through the production of IL-2 and 
pro-survival factors. NFAT’s binding partners are also critical for T cell activation. 
Recently, the genetic targets of NFAT were further characterized, comparing 
constructs that allowed or ablated binding with its most common partner, AP-1. A 
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subset of genes critical for the promotion of CD8+ T cell exhaustion were highly 
dependent on NFAT, with transcription occurring in the absence of AP-1 
(Martinez et al., 2015a). The amount of time that NFAT spends inside the 
nucleus is critical for specific transcriptional targets. Using multiphoton intravital 
microscopy, the half-lives of NFAT nuclear import and export were calculated to 
be ~1min for import and ~20min for export. The tolerance gene Egr2 was 
sensitive to short low affinity antigen stimulation, while the effector gene Ifng 
needed prolonged high affinity stimulation (Marangoni et al., 2013).  
ITK	and	Graded	TCR	Signal	Strength	
Downstream of Lck, the LAT signaling complex is critical for subsequent 
signaling pathway activation. Inducible T cell kinase (ITK) is a Tec family tyrosine 
kinase, which is activated by Lck and phosphorylates PLCγ. Unlike its sister 
kinase Bruton’s tyrosine kinase (BTK), ITK’s expression is largely limited to T 
cells and its catalytic activity is in the weak micromolar range.  In resting T cells, 
ITK resides in the cytosol. Upon activation, the kinase is recruited to the plasma 
membrane through its pleckstrin homology (PH) domain, which binds 
PtdIns(3,4,5)P3 (PIP3). ITK also associates with the LAT-SLP76 complex through 
its SH2 and SH3 domains, creating a signaling complex that is directly 
dependent on upstream Lck and Zap70 signaling. ITK is directly phosphorylated 
by Lck and subsequently undergoes cis-autophosphorylation. Then, ITK is able 
to phosphorylate the lipase PLCγ that cleaves PIP2 in the plasma membrane, 
generating the secondary messengers IP3 and DAG (Andreotti et al., 2018). 
These secondary messengers primarily activate the downstream MAPK, NF-κB, 
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and calcium signaling pathways (Berg, 2007; Berg et al., 2005; Schwartzberg et 
al., 2005). 
Unlike the upstream Src kinases, ITK is not required for T cell activation. 
Indeed, Itk-deficient T cells are capable of proliferation and cytokine production in 
response to antigen stimulation (Liao and Littman, 1995; Liu et al., 1998). Mice 
lacking ITK are also able to clear pathogens in multiple infection models 
(Bachmann et al., 1997; Fowell et al., 1999; Schaeffer et al., 1999). However, Itk-
deficient T cells are not normal, and a diminished response is observed rather 
than an ablated response. While the MAPK pathway is only modestly impaired in 
Itk-deficient T cells, the magnitude of calcium flux is greatly reduced in response 
to antigen (Miller et al., 2004). This reduction in signaling correlates with a 
reduction in CD8+ T cell clonal expansion in response to infection (Atherly et al., 
2006a). A key set of experiments directly compared kinase dead mutants of Lck 
and ITK overexpressed in activated T cells (Donnadieu et al., 2001). While both 
mutants inhibited calcium flux in the T cells, the mutants had very different effects 
on the whole population. The Lck mutants ablated calcium signaling in a 
proportion of the T cells, only cells with lower expression of the mutant were able 
to flux calcium. Conversely, ITK mutants dampened the calcium response of 
each cell expressing the mutant in the entire population, both in amplitude and 
duration. This suggests a digital regulation of calcium signaling through Lck and 
an analog regulation through ITK. A simplified model of TCR and ITK signaling 
that drives changes in T cell transcription is shown in Figure 1.1.  
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Figure 1.1: Representative model of TCR signaling and regulation of 
transcription in activated CD8+ T cells. 
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Figure 1.1: Representative model of TCR signaling and regulation of 
transcription in activated CD8+ T cells. 
This is a simplified model of TCR signaling in CD8+ T cells, focusing on the 
downstream pathways that alter transcription in early activated cells: MAPK, NF-
κB, and Calcium. This model also highlights the LAT signaling complex and the 
Tec kinase ITK, which phosphorylates PLCγ leading to generation of the 
secondary messengers DAG and IP3 acting as the anchor points for cytoplasmic 
signaling cascades. 
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Graded	TCR	Signaling	and	Transcription	Factors	
In addition to the canonical transcription factors AP-1, NF-κB, and NFAT, 
which are activated by the TCR, CD8+ T cells rely on a diverse set of 
transcription factors that drive different functions. Recently, the balance of Blimp-
1, T-Bet, Bcl-6, and Eomesodermin have been linked to changes in CD8+ T cell 
differentiation with high TCR signal strength driving T-Bet and Blimp-1 
expression, leading to terminal effector differentiation (Daniels and Teixeiro, 
2015; Joshi et al., 2007; Kaech and Cui, 2012). Changes in transcription have 
also been linked to TCR affinity, specifically the transcription factor Interferon 
Regulatory Factor 4 (IRF4) (Huber and Lohoff, 2014). While it shares homology 
with other family members like IRF3, Type 1 IFN does not regulate IRF4 (Honda 
and Taniguchi, 2006). Rather, its expression is directly regulated by antigen 
receptors in both T cells and B cells. Undetectable in naïve lymphocytes, IRF4 is 
rapidly upregulated by antigen stimulation and the magnitude of expression is 
proportional to the strength of stimulus (Nayar et al., 2012).The NF-κB family 
transcription factor c-Rel directly regulates Irf4 at the promoter locus (Grumont 
and Gerondakis, 2000). In CD8+ T cells, IRF4 expression directly impacts clonal 
expansion and viral clearance. Specifically, the amount of IRF4 expressed in the 
CD8+ T cell contributed to the expansion of terminal effector cells (TECs) (Man et 
al., 2013; Nayar et al., 2014; Yao et al., 2013). These terminally differentiated T 
cells are critical for pathogen control and require robust proliferation before the 
population contracts through apoptosis. IRF4 contributes to TEC functionality by 
regulating multiple genes associated with glycolysis (Man et al., 2013; Man and 
Kallies, 2015).  
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CD8+ T cells rapidly shift their metabolism in response to antigen and like 
cancer cells, use glycolytic pathways to increase glucose import providing energy 
and macromolecules for biomass expansion and division (Pearce et al., 2013; 
2009). IRF4 can also act as a repressor and binds sites in genes associated with 
apoptosis and cell cycle inhibition, supporting its important role in T cell survival 
and expansion (Yao et al., 2013). Directly comparing Irf4+/fl with Irf4fl/fl (using 
CD4-Cre) and WT mice, viral clearance and TEC expansion was directly 
proportional to the maximum level of IRF4 expression. The haploinsufficient mice 
had approximately 2-5 fold less IRF4 production, a reduction that was mirrored in 
their ability to clear infection (Nayar et al., 2014). Reduction in TCR signaling is 
also linked to impaired protein translation and ribosome biogenesis in OT-I T 
cells stimulated with low affinity ligand with and without Lck (T. C. J. Tan et al., 
2017). 
CD4+ T cells, or “helper T cells” are often characterized by their ability to 
produce cytokines in response to TCR stimulation. Various subsets have been 
defined: TH1, TH2, TH9, TH17, and TREG are the most commonly studied subsets. 
TH1 T cells are mainly defined by their ability to secrete IFNγ with TH2, TH9, and 
TH17 cells producing IL-4, IL-9, and IL-17 respectively. TREGs are a subset of T 
cells that produce the immunosuppressor IL-10 in response to auto-antigen 
stimulation (Kaplan et al., 2015; Murphy and Reiner, 2002; Walker and 
McKenzie, 2018). IRF4 expression levels controlled TH9 and TH17 differentiation 
and IL-9/IL-17 production (Gomez-Rodriguez et al., 2016; 2014). In the absence 
of ITK, differentiation was inhibited and was rescued by exogenous IRF4 
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transduction. TR1 cells, a IL10hiFoxp3lo population of Tregs, are also dependent 
on ITK activity, driven by Ras pathway-mediated induction of IRF4 (Huang et al., 
2017). In humans, IRF4 haploinsufficiency was linked to a rare inactivating 
mutation at R98W leading to impaired transcription factor activity. This led 
carriers to be more susceptible to Tropheryma whipplei infection, a bacterium 
normally controlled in the majority of the population (Guérin et al., 2018).  
The frequent binding partner of IRF4, BATF, has also been linked to CD8+ 
T cell expansion. However, unlike IRF4, the levels of expression are not as 
critical. The two transcription factors are regulators of T-bet and Blimp1 
expression, the two transcription factors that drive effector differentiation (Kurachi 
et al., 2014). Interestingly, BATF was determined to act as a “persistence 
detector” of antigen signaling. Maximum BATF-mediated effector differentiation 
was only triggered by durable antigen signaling. Late in the T cell response, 
BATF could also repress critical genes like Perforin and Granzyme B, dampening 
the late effector response (Kurachi et al., 2014). Further research led to 
identification of a DNA binding motif that was occupied by BATF-IRF4 only in TH2 
cells stimulated with high dose antigen (Iwata et al., 2017).  
Another factor associated with TCR affinity is Nur77, a transcription factor 
primarily associated with apoptosis (Woronicz et al., 1994). Nur77 is often used 
as a reporter for TCR activation with its expression proportional to antigen 
avidity. The amount of Nur77 expression correlates with thymic selection, with 
negatively selected thymocytes having higher levels than their positively selected 
counterparts (Baldwin and Hogquist, 2007; Moran et al., 2011). Nur77 is rapidly 
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upregulated after antigen stimulation and its expression is dependent solely on 
TCR signaling. Using a Nur77-GFP reporter mouse, the levels of GFP were 
proportional to the affinity of TCR ligand in the OT-I model system, showing a 
graded expression similar to IRF4 (Moran et al., 2011). However, a binary 
response was observed in activated CD8+ T cells stimulated with different doses 
of antigen. The threshold of Nur77-GFP reporter activation was then connected 
to IL-2, with exogenous IL-2 leading to a lower threshold of reporter expression 
(Au-Yeung et al., 2017).  
The signaling data suggests that certain factors like CD69 and IL-2 are 
digital in nature, while others like IRF4 are analog in nature. The strength of TCR 
stimulus, whether through increased dose or affinity of antigen, is not 
proportional to the output of the MAPK and NF-κB signaling pathways. However, 
the activation marker IRF4 is proportional to the strength of stimulus. 
Graded	TCR	Signaling	and	CD8+	Effector	Function	
CD8+ T cell development and function have been studied using the OT-I 
transgenic mouse model. The OT-I TCR recognizes the SIINFEKL peptide (N4), 
an antigen derived from chicken ovalbumin (Hogquist et al., 1994). These OT-I T 
cells are MHC class I restricted, creating a large population of naïve CD8+ T cells 
that recognize the peptide antigen. The OT-I model provides an excellent system 
to study TCR signal strength because of the exquisitely high affinty N4 peptide 
ligand. Altered peptide ligands (APLs) with single amino acid substitutions greatly 
reduce TCR binding affinity while maintaining equivalent MHC-I binding capacity. 
Scientists have also engineered a variety of pathogens to express these APLs, 
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providing excellent infection models to study TCR signal strength in vivo. In the 
context of CD8+ T cell development in the thymus, graded TCR signal strength 
drives the balance between positive and negative selection, a process that can 
directly impact autoimmune disease (Daniels et al., 2006; Enouz et al., 2012; 
Koehli et al., 2014). By designing a DNA-based chimeric antigen receptor, 
researchers were recently able to show that a single hydrogen bond, added 
through nucleotide substitution, could increase both antigen binding and 
downstream receptor signaling, emphasizing the importance of the affinity of the 
antigen for the TCR on signaling dynamics (Taylor et al., 2017). 
A series of studies have looked at CD8+ T cell activation in vivo in 
response to infection and have teased apart contributions between antigen 
interactions and environmental inflammatory signals. While T cell expansion was 
directly proportional to antigen avidity, cytolytic function was more dependent on 
inflammatory signals (Zehn et al., 2009; 2013). Using peptide-pulsed dendritic 
cells with or without Listeria monocytogenes infection, Granzyme B and IFN-γ 
production were only seen in the context of infection. However, IL-2 and the 
chemokine receptor CCR7 were regulated in the absence of inflammation and 
their expression was directly proportional to the avidity of the antigen. The high-
affinity IL-2 receptor (CD25) was driven by both signals with its expression 
proportional to both dose and affinity of the stimulus (King et al., 2012; Zehn et 
al., 2009). These Listeria experiments show that certain aspects of T cell function 
are driven by the affinity of the pMHC-TCR interaction, while others are driven by 
cytokine activation. Low affinity antigen stimulation downregulated CCR7 earlier 
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than high affinity stimulation and the T cells were able to migrate out of the 
periarteriolar lymphocyte sheaths (PALS) at an earlier time, creating a larger 
proportion of T cells in the blood and the red pulp of the spleen. The high affinity 
stimulated T cells retained CCR7 expression out to 4d and did not migrate out of 
the PALS. Further confirmation of this phenotype followed with recent studies 
using intravital imaging of lymph nodes in OT-I mice stimulated with transferred 
peptide-pulsed dendritic cells. TCR affinity did not control early APC:T cell 
contact, however, sustained contact past 24h was only observed with high affinity 
N4 antigen. These high affinity clones then migrated to interfollicular regions, a 
process mediated by CXCR3 (Ozga et al., 2016).  
Effects on T cell migration and tissue infiltration were also observed in the 
context of autoimmunity. In a model where membrane-bound ovalbumin (mOVA) 
is under the control of the rat insulin promoter (RIP), OT-I T cells were 
transferred into mice after immunization with high and low affinity peptide 
antigen. This model is useful in that antigen is expressed specifically in the 
pancreas and OT-I T cells can recognize the antigen even in the absence of 
infection. Only T cells stimulated with high affinity peptide were able to infiltrate 
the pancreas and migrate to the site of antigen, a process that was dependent on 
the integrin VLA-4 (King et al., 2012). 
The altered expression in both magnitude and kinetics of CD25, CD69, 
and CCR7 show that antigen affinity directly affects IL-2 signaling and lymph 
node egress. This suggests that T cells stimulated with high-affinity antigen are 
able to sequester more IL-2 from the environment and remain in the lymph node, 
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thereby allowing them a longer time to receive stimulation. This delay in egress 
contributes to a more robust clonal expansion, a process that is directly 
proportional to antigen avidity. Signaling through the IL-2 receptor is required for 
CD8+ T cell memory formation (Malek, 2008). Mice lacking IL-2 receptors in 
mature CD8+ T cells, mixed chimeras that retain a normal population of T 
regulatory cells, were able to mount a normal primary response to LCMV 
infection. However, the secondary response was impaired. Thus IL-2 signaling is 
required during the primary response to produce a functional memory pool 
(Williams et al., 2006). IL-2 can also promote proliferation of T cells stimulated by 
low-affinity antigen. Using an in vitro co-culture system of P14 and OT-I CD8 T 
cells, P14 T cells stimulated with high-affinity GP33 peptide could produce IL-2 
and trigger increased proliferation in neighboring OT-I T cells that were 
stimulated with the low-affinity G4 peptide. The IL-2 is required within 20-30h of 
antigen stimulation and PI3K signaling through the IL-2 receptor cooperates with 
TCR signaling to promote cell cycle entry (Voisinne et al., 2015). IL-2 is not the 
only secondary signal that cooperates with TCR activation, a wide variety of co-
stimulatory pathways interplay with graded TCR signaling to promote diverse 
CD8+ T cell functions (L. Chen and Flies, 2013). The regulation of T cell memory 
has been extensively linked to a combination of graded TCR signaling and co-
stimulation using multiple transgenic and pathogen models (Daniels and Teixeiro, 
2015). 
Affinity of the antigen has also been linked to regulation of asymmetric cell 
division with proximal daughter T cells becoming TECs (Chang et al., 2007; King 
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et al., 2012). High affinity interactions led to a distinct progeny after the first 
division with proximal daughters containing the immunosynapse and increased 
glycolytic capacity. In contrast, low affinity TCR interactions did not lead to this 
phenotype. Single-cell genomic studies revealed that changes in TCR affinity did 
not alter the T cells cytotoxic function, rather changes in transcriptional 
upregulation were delayed (Richard et al., 2018). Graded TCR signaling controls 
many aspects of CD8+ T cell differentiation. The signaling mechanisms that 
connect graded TCR stimulation with these changes in differentiation while not 
completely understood have been extensively examined in the recent years 
(Kaech and Cui, 2012; Zikherman and Au-Yeung, 2015). 
CD28	Costimulation	and	Autoreactive	T	Cell	Migration	
Since early work discovering that TCR ligation by itself induced T cell 
anergy, constimulatory signals presented by APCs were known to be critical for T 
cell activation (Jenkins et al., 1988; Mueller et al., 1989). Discovery of the CD28 
receptor and its cognate ligands of B7-1 (CD80) and B7-2 (CD86) on APCs soon 
followed (Jenkins et al., 1991). Dosing mice with CD28 antagonists induced 
tolerance in organ engraftment experiments, suggesting a role in controlling 
autoreactive T cells (Lenschow et al., 1992). This then lead to the 
characterization of CTLA-4, a competitive receptor for B7, which inhibited T cell 
activation. CTLA-4 binds more strongly to B7 ligands, contributing to its dominant 
role as a T cell suppressor, now considered an immune checkpoint similar to PD-
1 (Leach et al., 1996).  
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CD28 resides on the surface of the plasma membrane as a 44 kDa 
homodimer, with important cytoplasmic tail domains that are required for 
downstream signaling (Carreno and Collins, 2002). These motifs include 3 
tyrosine residues that are phosphorylated after TCR stimulation and bind multiple 
signaling proteins critical for signal transduction, GRB2, VAV3, PI3K, SLP-76, 
and CSK to name a few. Proline-rich sequences can also bind SH3 domains of 
other signaling proteins. These signaling domains are critical for different T cell 
functions, one of which is IL-2 production, a process dependent on CD28 (Fraser 
et al., 1991; June et al., 1987; Thompson et al., 1989). Importantly, Src kinase 
Lck can also interact with CD28 through its SH3 domain, creating a codependent 
signaling mechanism uniting TCR and CD28 pathways (Holdorf et al., 1999). Lck 
can phosphorylate the tyrosines in the CD28 tail. The main function of CD28 
signaling in CD8 T cells seems to be the regulation of the cells glycolytic rate 
through Akt and mTORC1 activation, a process that is also highly regulated by 
IRF4 (Frauwirth et al., 2002; Man et al., 2013).  
The complexity of CD28 biology, and co-stimulation in general, is beyond the 
scope of this thesis. We were interested in exploring one key function of T cells, 
transendothelial migration, a process that required both CD28 and ITK signaling 
in an autoimmune pathology model (Jain et al., 2013). Briefly, transendothelial 
migration is a multi-step process by which T cells (and generally other cell types) 
bind to integrins on the surface of the endothelium. The “stop” binding step is 
then followed by a “rolling” step which halts the T cell in place before it can 
migrate through the tight junctions between the endothelial cells and pass 
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through to other tissues. This complex process is largely driven by the selectins 
(P- and E-selectin) and integrin ligands ICAM-1 and VCAM-1 (Vestweber, 2015). 
Summary	of	Key	Research	Questions	
The connection between ITK activity and IRF4 was first identified in a 
microarray experiment comparing CD8SP thymocytes from WT and Itk-/- mice. 
IRF4 expression was reduced in the KO cells (Nayar et al., 2012). Nayar et. al. 
then went on to further explore the relationship between the kinase and the 
transcription factor in T cells. Comparing Itk-/- and Irf4fl/fl (under control of CD4-
Cre) mice, their peripheral T cells showed an innate/memory phenotype with 
CD44hiCD62Lhi expression. They both also had very high levels of Eomes, a 
transcription factor associated with T cell memory. Stimulation of T cells with high 
and low doses of CD3 and CD28 antibodies along with treatment with a small 
molecule inhibitor or ITK, 10n, resulted in a graded inhibition of IRF4 expression 
that was dose-responsive. These experiments gave us the first evidence that ITK 
activity could fine-tune IRF4 expression, however the mechanism was unknown 
(Nayar et al., 2012). 
Shortly thereafter, a series of papers went on to describe the importance 
of IRF4 function in CD8+ T cells, specifically in the context of clonal expansion in 
response to infection. Irf4-/- CD8+ T cells were unable to clear L. monocytogenes 
infection due to their impaired proliferation, cytotoxicity, and cytokine production. 
The T cells also expressed lower levels of T-bet, Blimp-1, and Id2, transcription 
factors critical for TEC function (Raczkowski et al., 2013). A similar defect in 
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clonal expansion was observed in the context of LCMV and Influenza A infection 
(Man et al., 2013; Nayar et al., 2014) (Yao et al., 2013). 
Nayar et al went a step further and compared Irf4fl/fl and Irf4+/fl T cells. 
Haplosufficient T cells had about 2-fold less IRF4 expression and also had 
defective clonal expansion post infection. Importantly, these haplosufficient mice 
are able to control the LCMV infection and viral load is undetectable at d8, unlike 
knockout mice who still have active infection. This allows for a better comparison 
of Irf4+/+ and Irf4+/fl CD8+ T cells during their expansion and contraction phases, 
eliminating any confounding inflammatory factors present in mice with viral 
burden. Adoptive transfer experiments with P14 T cells, the TCR specific for the 
GP33 epitope of LCMV, confirmed an intrinsic CD8+ T cell defect in clonal 
expansion caused by a 2-fold reduction in IRF4 expression (Nayar et al., 2014). 
Man et. al. went on to link IRF4 to aerobic glycolysis with RNA-seq experiments 
comparing Irf4+/+ and Irf4-/- T cells. Yao et. al. connected IRF4 function to cell 
cycle progression and survival with defects in CDK inhibitors and Bim expression 
(Man et al., 2013; Yao et al., 2013). These papers provided a rationale for 
looking at IRF4 regulation in CD8+ T cells, because of the defect in clonal 
expansion seen with a modest decrease in expression. There were also striking 
similarities between the anti-viral responses of Itk-/- and Irf4+/fl mice, with both 
CD8+ T cell populations able to clear LCMV infection with delayed kinetics of 
clonal expansion (Atherly et al., 2006a; Nayar et al., 2014).  
While the OT-I TCR transgenic mouse has been used to study CD8+ T cell 
biology for quite some time, a watershed paper by Zehn et.al. pushed the model 
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much further and characterized the response of OT-I T cells to altered peptide 
ligands (APLs) in vivo (Zehn et al., 2009). This provided the foundation for our 
experiments studying graded TCR signaling. We wanted to take a reductionist 
approach where we could use a clonal population of CD8+ T cells and look at 
their response to varying strengths of TCR stimulus by using the described APLs 
or blocking ITK activity using knockout mice or a small molecule inhibitor. This 
system also allowed us to compare the effect of antigen dose and affinity on 
different early response genes, teasing apart contributions from both inputs. This 
model system shares all the caveats of T cell stimulation in cell culture, however, 
in these experiments primary APCs are used rather than supraphysiological 
stimulation of the TCR by antibody crosslinking, a method that has been mostly 
used in signaling experiments because of the difficulty in looking at signaling 
dynamics using single-cell methods like flow cytometry. We wanted to use new 
technological methods that would allow single-cell detection while also keeping 
intact the APC:T cell relationship. Using this model system to carefully test TCR 
signal transduction, we set out with one main objective: Determine the 
mechanism by which TCR signaling drives graded IRF4 expression in CD8+ 
T cells.  
It was known that Itk-/- T cells had a defect in calcium signaling. T cells 
stimulated with CD3 antibody were inhibited in their ability to flux calcium (Miller 
et al., 2004) and elegant experiments using T cells expressing a kinase dead 
mutant of ITK also revealed a calcium flux defect, specifically in the amplitude of 
signal observed with the indicator dye (Donnadieu et al., 2001). We reasoned 
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that this calcium signaling deficiency could be contributing to the lower IRF4 
levels in ITK inhibited T cells. (Figure 1.2) 
Itk-/- T cells are able to turn on p-Erk in response to TCR activation, 
suggesting that the MAPK pathway is unlikely to play a role. Excellent work by 
Das et.al. described a digital signaling network controlling the MAPK pathway in 
T cells. Using modeling and experimental data, they showed that CD69 has a 
binary response to Ras signaling and also that the Ras pathway has a positive 
feed-forward loop leading to digital p-Erk activation (Das et al., 2009). We posited 
that CD69 would be regulated differently by TCR signaling, when compared to 
IRF4, and is likely not regulated by ITK activity in the same way. (Figure 1.2) 
 
  
 26 
Figure 1.2: Our hypothesis that TCR signal strength and ITK activity control 
graded IRF4 expression through the calcium-sensitive transcription factor 
NFAT.  
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Figure 1.2: Our hypothesis that TCR signal strength and ITK activity control 
graded IRF4 expression through the calcium-sensitive transcription factor 
NFAT.  
While the expression of genes like CD69 and IL-2 is not directly proportional to 
the signaling input of the TCR, other genes like IRF4 have a graded response 
where expression continues to increase with higher affinity TCR stimulation. 
High-affinity antigens increase the during of TCR binding, increasing the stability 
of Lck and ZAP70, which amplifies downstream signaling by creating a larger 
pool of activated LAT signaling complexes. This creates a larger pool of activated 
ITK, represented here for simplification without the other signaling components in 
the pathway. We propose that the calcium signaling pathway is uniquely 
sensitive to ITK and can provide a mechanism for graded IRF4 expression. 
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In another context of T cell function, Jain et. al. described a striking phenotype 
when Ctla4-/- mice were crossed to Itk-/-. The disease pathology caused by 
infiltration of autoreactive T cells into multiple tissues, eventually leading to 
death, was completely prevented in the double knockout mice. The T cells 
retained their autoreactive proliferative capacity, however, now coupled with an 
inability to migrate out of the secondary lymphoid organs. Thus, disease 
prevention was due to the lack of pathological infiltration into lung, liver, and 
pancreatic tissue. Using 2-photon microscopy, labeled Itk-/- T cells were 
transferred into WT mice and then imaged in the lung. The cells lacking ITK were 
observed in the endothelium, rounded in shape and unable to crawl along the 
walls of the blood vessles, an early step in TEM (Jain et al., 2013).  King et. al. 
connected TCR signal strength with autoreactive tissue pathology in the RIP-
mOVA / OT-I diabetes (T1D) induction model, where Ova antigen is expressed in 
the β-islet cells of the pancreas. They described a sharp threshold in TCR affinity 
that lead to T1D induction with immunization of transferred OT-I T cells with high 
affinity antigen leading to pancreatic infiltration and low affinity antigen unable to 
cause disease (King et al., 2012). These experiments lead us to speculate that 
ITK-dependent regulation of IRF4 could be involved in the autoreactive T cell 
migratory defect.  
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Thesis	Objectives	
Based on these studies, we hypothesized that changes in IRF4 expression, 
driven by the strength of TCR stimulus, are controlled by changes in the 
calcium signaling pathway. We also hypothesized that TCR and CD28 
signaling synergized to control IRF4 expression in the context of 
autoreactive T cell migration. These hypotheses are described in the following 
two chapters: 
Chapter III: TCR signal strength controls dynamic NFAT activation 
threshold and graded IRF4 expression in CD8+ T cells. 
This chapter involves experiments testing our hypothesis that IRF4 regulation is 
mediated by calcium signaling in activated CD8+ T cells. We use multiple single-
cell techniques to look at changes in the calcium signaling pathway and its 
connection to transcription through NFAT activation. We then connect NFAT 
activity to IRF4 upregulation. 
Chapter IV: TCR signal strength controls selectin binding and autoreactive 
CD8+ T cell migration.  
This chapter involves experiments testing our hypothesis that selectin binding, an 
early step in T cell transendothelial migration, could be sensitive to changes in 
TCR signal strength. We then test contributions from CD28 costimulatory 
receptor signaling followed by in vivo functionality in an adoptive transfer model 
of autoreactive T cell migration.  
 30 
 
 
 
 
 
 
 
 
 
 
CHAPTER	II:	MATERIALS	AND	METHODS	
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Mice: 
Mice were bred and housed in specific pathogen-free conditions at the University 
of Massachusetts Medical School (UMMS) in accordance with Institutional 
Animal Care and Use Committee (IACUC) guidelines. 
Chapter III: 
OTI Rag-/- (B6.129S7-Rag1tm1Mom Tg(TcraTcrb)1100Mjb N9+N1) were purchased 
from Taconic (Hudson, NY). CD45.1 (B6.SJL-Ptprca Pep3b/BoyJ) were 
purchased from The Jackson Laboratory (Bar Harbor, ME). OTI Rag-/- Itk-/- 
CD45.1 mice were generated by crossing Itk-/-, OTI Rag-/- and CD45.1 mice. Itk-/- 
mice have been described previously (Liu et al., 1998). Nur77-GFP reporter mice 
(a gift from Dr. S. Swain, UMMS) were crossed to OTI Rag-/- mice. Nur77-GFP 
reporter mice have been described previously (Moran et al., 2011). For 
experiments, mice at 8-12 weeks of age were used.  
Chapter IV: 
OTI Rag-/- (B6.129S7-Rag1tm1Mom Tg(TcraTcrb)1100Mjb N9+N1) were purchased 
from Taconic (Hudson, NY). CD45.1 (B6.SJL-Ptprca Pep3b/BoyJ) and RIP-mOVA 
(Tg(Ins2-TFRC/OVA)296Wehi) mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME). OTI Rag-/- Itk-/- CD45.1 mice were generated by 
crossing Itk-/-, OTI Rag-/- and CD45.1 mice. Itk-/- mice have been described 
previously (Liu et al., 1998). B7-/- (Cd80-/- Cd86-/-) mice were a gift from J. Kang 
and have been described previously (Borriello et al., 1997). For experiments, 
mice at 8-12 weeks of age were used.  
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Cell culture: 
Chapter III: 
Splenocytes from OT-I Rag-/- mice (and the genetic variants) were stimulated ex-
vivo with recombinant peptide (N4, T4, or G4) at the indicated doses for 24h. 
Antigen-presenting-cells (APCs) in the bulk splenocyte population were sufficient 
for stimulation. (Figures 1-2) Recombinant peptides were purchased from 21st 
Century Biochemicals (Marborough, MA). PRN694 was generously provided by 
Principia Pharmaceuticals (Zhong et al., 2015). For stimulation readouts earlier 
than 24h, OT-I T cells were stimulated at a 5:1 ratio of APCs to T cells. The 
APCs used were bulk splenocytes isolated from WT C57BL/6 mice, then pulsed 
with peptide prior to the addition of T cells. (Fig. 4) APCs used in Fig. 5 were 
stimulated with LPS (1ug/mL) and pulsed with peptide for 1h prior to addition of T 
cells. LPS, FK506, PMA, and Ionomycin were purchased from Sigma-Aldrich (St. 
Louis, MO).  
Chapter IV: 
Splenocytes from OT-I Rag-/- mice (and the genetic variants) were stimulated ex-
vivo with APCs pulsed with recombinant peptide (N4, T4, or G4) at the indicated 
doses for 24-48h. APCs were bulk splenocytes from WT (C57BL/6) or B7-/- mice 
stimulated with LPS (1ug/mL) and pulsed with peptide for 1h prior to addition of T 
cells. Recombinant peptides were purchased from 21st Century Biochemicals 
(Marborough, MA). LPS was purchased from Sigma-Aldrich (St. Louis, MO). 
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PRN694 was generously provided by Principia Biopharma Inc (Zhong et al., 
2015).  
 
Antibodies and flow cytometry: 
Chapter III: 
IRF4 (eF660 and PE), CD8a (PE-eF610), Va2 (APC and APC-eF780), TCRb 
(APC-eF780), Eomes (PE and PE-Cy7), T-bet (PerCP-Cy5.5), CD45.1 (eF450 
and APC-eF780), CD69 (FITC and PE-Cy7) were purchased from eBioscience / 
Thermo Fisher (San Diego, CA). CD44 (v500) and CD45.1 (BV510) were 
purchased from BD Biosciences (Billerica, MA). LIVE/DEAD Violet, LIVE/DEAD 
Aqua, goat anti-rabbit (PE) were purchased from Life Technologies (Grand 
Island, NY). Single cell suspensions were prepared from isolated spleens; RBCs 
were lysed; Fc receptors were blocked using supernatant from 2.4G2 
hybridomas. Intracellular transcription factor staining was performed using 
eBioscience FoxP3 Transcription Factor Staining Buffer Set. Samples were 
analyzed on the LSR II flow cytometer (BD Bioscience) and data was analyzed 
on Flow Jo (Tree Star).  
Chapter IV: 
IRF4 (eF660 and PE), CD8a (PE-eF610), Va2 (APC and APC-eF780), TCRb 
(APC-eF780), CD226 (APC), CD25 (PE-Cy7), CD45.1 (eF450 and APC-eF780), 
CD69 (FITC and PE-Cy7) were purchased from eBioscience / Thermo Fisher 
(San Diego, CA). CD44 (v500), CD45.1 (BV510), and purified recombinant 
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mouse P-selectin – human IgG fusion protein were purchased from BD 
Biosciences (Billerica, MA). LIVE/DEAD Violet and goat anti-human IgG1 Fc 
(APC) were purchased from Life Technologies (Grand Island, NY). Single cell 
suspensions were prepared from isolated spleens; RBCs were lysed; Fc 
receptors were blocked using supernatant from 2.4G2 hybridomas. Intracellular 
transcription factor staining was performed using eBioscience FoxP3 
Transcription Factor Staining Buffer Set. Samples were analyzed on the LSR II 
flow cytometer (BD Bioscience) and data was analyzed on Flow Jo (Tree Star). 
 
Nuclear flow and RNA flow:  
Chapter III: 
Nuclei isolation and flow cytometry staining of OT-I cells stimulated in co-cultures 
were performed as previously described (Gallagher et al., 2018).  Briefly, CD8+ T 
cells were negatively enriched from OT-I spleens (Stemcell Technologies) and 
labeled with CellTrace Violet cell tracking and proliferation dye (Thermo Fisher) 
for 20m prior to co-culture with peptide-pulsed B6 splenocytes. For nuclei 
isolation, cells were treated and washed with sucrose and detergent buffers. The 
nuclei were fixed in 4% paraformaldehyde and then intranuclear staining was 
performed with a 0.3% Triton-X 100 detergent PBS buffer. NFAT1-AF488 
antibody (clone D43B1) was purchased from Cell Signaling Technology 
(Danvers, MA). The PrimeFlow assay kit, from Thermo Fisher, was used for RNA 
flow. Cd69 and Irf4 probe sets were ordered for AF647.  
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ChIP analysis: 
Chapter III: 
NFAT1 ChIP-Seq data (GSE64409) from Martinez et. al. (Martinez et al., 2015a) 
was analyzed using Integrative Genomics Viewer (Broad Institute, Cambridge, 
MA) (Robinson et al., 2011). A snapshot was taken of the Irf4 gene locus.  
 
RIP-mOVA Adoptive Transfer Experiments: 
Chapter IV: 
For diabetes induction, 5 x 106 OT-I (Itk+/+ or Itk-/-) CD8 T cells were adoptively 
transferred intravenously into RIP-mOVA mice 1 day prior to immunization with a 
PBS solution containing 50µg of T4 peptide and 25µg of LPS by intraperitoneal 
injection, described previously (King et al., 2012). Urine glucose was monitored 
daily with test strips purchased from Roche Diagnostics. (Basel, Switzerland) 
Mice were sacrificed when urine glucose levels exceded 1000 mg/dL. For the 3-
day proliferation experiment, the OT-I T cells were labeled with CFSE (Life 
Technologies) and transferred and immunized in the same way. After 3d, the 
spleens were harvested for flow cytometry.   
 
Statistical analysis: 
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Graphs represent mean ± SEM. Statistical significance indicated by * p≤0.05, ** 
p≤0.01, *** p≤0.001, **** p≤0.0001 (NS, p>0.05) based on one-way ANOVA 
followed by Dunnett’s test or unpaired Student t test. Data analysis performed 
using GraphPad Prism 7.0 (GraphPad, San Diego, CA).  
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Introduction	
 A central process of the adaptive immune response to infection is the 
activation and expansion of cytotoxic T cells. Characterized by their expression 
of the co-receptor CD8, these lymphocytes are critical for identification and 
removal of intracellular pathogens. Activation of naïve CD8+ T cells is primarily 
driven by binding of MHC:peptide antigen to their T cell receptor (TCR). Upon 
receptor binding, a signaling cascade is triggered which directs the cell to 
respond by reorganizing its cytoskeleton, upregulating glycolytic pathways, and 
preparing for cell division and migration. The cell rapidly changes its 
transcriptional program and thousands of new genes are expressed to meet this 
new functional demand (N. Zhang and Bevan, 2011). While numerous studies 
have characterized the activated T cell transcriptome, detailed insight into 
pathways that link proximal TCR signaling dynamics to graded gene expression 
has remained elusive. 
 TCRs can bind to MHC:peptide complexes with wide variations of ligand 
binding kinetics.  Antigen abundance can also vary greatly, as a result of 
differences in pathogen burden and differing efficiencies of antigen presentation.  
Graded or variable responses to changes in TCR signal strength are known to 
generate diverse functional outcomes in responding T cells, a phenomenon best 
illustrated by the selection processes that shape the repertoire of developing T 
cells in the thymus (Klein et al., 2014).  The responses of peripheral T cells to 
infection or immunization are also modulated by variations in TCR signal 
strength.   When antigen doses are held constant, CD8 T cells with higher affinity 
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TCRs for MHC:peptide show a greater magnitude of expansion, and exhibit 
enhanced production of IFNγ relative to low affinity clones (Zehn et al., 2009).  
However, it remains unclear whether higher antigen doses are able to 
compensate for lower TCR affinity during peripheral T cell activation, or whether 
intrinsic differences in TCR interactions with MHC:peptide establish limits on the 
downstream outcomes of T cell activation.  
 
 The transcription factor Interferon Regulatory Factor 4 (IRF4) has been 
extensively characterized in lymphocytes(Huber and Lohoff, 2014).  For CD8+ T 
cells, the levels of IRF4 expression following T cell activation determine the 
magnitude of terminal effector cell (TEC) expansion in vivo (Man et al., 2013; 
Nayar et al., 2014; Yao et al., 2013). IRF4 expression is nearly undetectable in 
naïve and memory T cells, but is rapidly induced following TCR stimulation.  
Along with its frequent binding partner BATF, IRF4 upregulates a host of genes 
in newly-activated CD8+ T cells, specifically genes critical for the metabolic 
switch to glycolysis (Kurachi et al., 2014; Man et al., 2013). In TH2 cells, strength 
of TCR stimulation correlated with BATF-IRF4 binding to different enhancer 
regions of the genome, leading to variations in gene expression patterns (Iwata 
et al., 2017). While graded expression of IRF4, which changes the magnitude of 
the effector response, is dependent on TCR signal strength, the signaling 
mechanism regulating the control of IRF4 expression levels in CD8+ T cells is not 
completely understood.    
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 Our interest in the signaling pathway regulating graded IRF4 expression 
also derived from our previous findings that this process is controlled by the 
relative activity of the Tec kinase ITK (Nayar et al., 2012). A key molecule in TCR 
signal transduction, ITK is activated by the Src kinase Lck and recruited to the 
LAT signaling complex along with its substrate, phospholipase C (PLCγ).  Once 
activated, ITK phosphorylates and activates PLCγ. Activated PLCγ cleaves the 
membrane phospholipid PIP2 into the two secondary messengers diacylglycerol 
(DAG) and inositol triphosphate (IP3), which both help propagate downstream 
signaling pathways to regulate gene expression (Andreotti et al., 2018). To 
understand the signaling mechanisms that contribute to the graded levels of 
IRF4, we used the OT-I TCR transgenic mouse line along with altered peptide 
ligands (APLs) that change the signaling activity of the TCR without 
compromising MHC:peptide binding. In addition to using APLs, we used multiple 
methods to inhibit or inactivate the signaling molecule ITK.  
Using this reductionist approach, we varied both the MHC:peptide dose 
and the affinity of the TCR interaction with individual MHC:peptide complexes.  
Using this system to fine tune TCR signaling, we then employed several single-
cell assays to measure the consequences of varying TCR signal activity, thereby 
providing insight into the pathways contributing to graded expression of IRF4. We 
found that CD8+ T cells are able to integrate the digital activation of NFAT into 
graded IRF4 protein expression by varying the kinetics of activation.  
Furthermore, we showed that ITK activity contributes to TCR signaling by 
accelerating the rate of this response.  Thus, under conditions of weak TCR 
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signaling and/or in the absence of ITK activation, delayed kinetics of NFAT 
activation and Irf4 mRNA expression create a population of CD8+ T cells that, as 
shown previously (Atherly et al., 2006a; Nayar et al., 2014; 2015), has reduced 
proliferative capacity.  
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Results	
Weaker	TCR	signaling	reduces	maximum	effector-associated	gene	expression	in	CD8+	
T	cells		
In the first 24h after TCR stimulation, CD8+ T cells upregulate a variety of 
proteins that play key roles in T cell proliferation and cell trafficking. Two factors, 
CD69 and IRF4, are rapidly increased. Here, we used the TCR transgenic model 
OT-I to study CD8+ T cell activation in response to different peptide ligands that 
stimulate this TCR with differing potencies. The cognate peptide for the OT-I 
TCR is derived from chicken Ovalbumin, with the amino acid sequence of 
SIINFEKL (N4) (Hogquist et al., 1994). By substituting amino acids at the fourth 
position, TCR affinity for the MHC:peptide complex can be decreased without 
affecting peptide binding to MHC Class I (Zehn et al., 2009). For our studies, we 
used the SIITFEKL peptide (T4), which is approximately 100-fold less potent, and 
the SIIGFEKL peptide (G4), which is approximately 1000-fold less potent, than 
N4 (Rosette et al., 2001; Zehn et al., 2009).   
Initially, we performed dose response experiments in which each of the 
three peptides was added to unfractionated splenocytes from OT-I TCR 
transgenic x Rag2-/- (hereafter referred to as OT-I) mice, and cells were assessed 
24h later by flow cytometry.  For CD69 expression, as expected, a bimodal 
response was observed. At low peptide doses of T4 peptide, for instance, no 
CD69 upregulation was observed.  As the peptide dose increased, a threshold 
was reached where a subset of cells transitioned from low CD69 expression to 
high expression (Figure 3.1A, left panel).  At these intermediate doses, a mixture 
of CD69+ and CD69- cells was observed.  Plotting the percent CD69 positive 
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fraction at each peptide dose generated a steep dose response curve, indicative 
of an all-or-nothing binary response (Figure 3.1A, right panel). 
In contrast, simultaneous examination of IRF4 expression in the same cell 
populations showed a markedly distinct pattern of expression.  Like CD69, low 
peptide doses do not turn on IRF4. However, at higher peptide doses, IRF4 
levels continue to increase as peptide dose increases (Figure 3.1B).  If CD69 
expression is used as a minimal marker for activation, IRF4 levels continue to 
rise with higher peptide doses, even after the peak magnitude of CD69 is 
achieved. Simultaneously overlaying the  %CD69+ and IRF4 MFI line plots on 
the same graph illustrates this comparison, as highlighted by the area shaded 
(Figure 3.1C). The shallow slopes for the dose response curves for IRF4 
expression, as well as the variable slopes of these curves for peptides of different 
potencies, indicate that IRF4 regulation is not binary in nature; rather, IRF4 
expression levels are tunable by TCR signal input.  Correspondingly, a significant 
difference in maximum IRF4 expression levels are seen when comparing the 
responses to the three different peptides, with maximal expression proportional 
to TCR affinity (Figure 3.1D).  
To determine whether differences in peak expression levels of IRF4 in 
response to stimulation with different potency peptides might result from altered 
kinetics of IRF4 gene expression, we examined CD69 and IRF4 levels on  
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Figure 3.1. CD69 and IRF4 respond differently to graded TCR signaling in 
activated CD8+ T cells. 
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Figure 3.1. CD69 and IRF4 respond differently to graded TCR signaling in 
activated CD8+ T cells.  
(A) Representative histogram plots of CD69 staining on OT-I cells stimulated with 
different doses of T4 peptide for 24h. Cells were gated on live CD8+ TCRβ+. Plots 
of %CD69+ values are shown for all three peptides at right.  
(B) Representative histogram plots of IRF4 intracellular staining in OT-I cells 
stimulated with different doses of T4 peptide for 24h. Cells were gated on live 
CD8+ TCRβ+. Plots of IRF4 MFI values are shown for all three peptides at right. 
(C) IRF4 MFI and %CD69+ values for the T4 peptide dose response were plotted 
on the same graph. The area shaded in gray emphasizes the concentration of 
antigen that yields maximum CD69 expression but is still on the upslope for IRF4 
expression.  
(D) IRF4 MFI values were normalized to N4 stimulation over multiple 
experiments. These data show results of stimulations with 1nM N4, 100nM T4, 
and 1µM G4, which are the relative concentrations eliciting maximum IRF4 
expression for each peptide. ** p≤0.01, *** p≤0.001, **** p≤0.0001 (one-way 
ANOVA followed by Dunnett’s test for N4 comparisons. Unpaired student t test 
for T4 and G4 comparison) 
(E) OT-I T cells were stimulated for 12-48h with 1nM N4, 100nM T4, or 1µM G4. 
MFI values for CD69 (left) and IRF4 (right) are plotted over time.  
Data are representative of three to five experiments.  
 47 
stimulated OT-I cells at 12, 24, 36, and 48h post-stimulation. These data clearly 
indicate that the affinity-based maximum expression of IRF4 was not due to a 
delay in the timepoint at which maximal IRF4 expression was achieved. Instead, 
we observed maximum levels of IRF4 at 24-36h post-stimulation, regardless of 
the peptide used to stimulate the T cells. Similar kinetics of CD69 induction were 
also observed with all 3 peptides (Figure 3.1E).  Overall these results show that 
IRF4 expression levels are a sensitive measure of TCR signal strength, and are 
sensitive to both the dose of antigen as well as the strength of binding of each 
TCR to peptide-MHC.   
We next examined other genes known to be regulated by TCR signaling.  
For these studies, we first chose Nur77 (Nr4a1) induction, a response commonly 
used to monitor TCR signal strength both in vitro and in vivo. (Baldwin and 
Hogquist, 2007; Moran et al., 2011; Woronicz et al., 1994)  OT-I mice were 
crossed to the Nur77-GFP reporter line (Moran et al., 2011), and OT-I CD8+ T 
cells were stimulated in bulk splenocyte cultures with varying doses of each of 
the three Ova peptides (N4, T4, and G4).   Unlike the pattern of expression 
observed for IRF4, Nur77-GFP peak expression levels were not dependent on 
the peptide potency (Fig. 3.2A, left and middle panels).  In each case, higher 
doses of lower potency peptides were able to achieve the same levels of GFP 
expression as the strongest N4 peptide.  This pattern of expression was 
independent of the timepoint examined, as timecourse studies showed 
overlapping kinetics of Nur77-GFP expression regardless of the peptide used to 
stimulate the T cells (Figure 3.2A, right panel). Thus, while Nur77 reporter 
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expression is closely linked to TCR activation in vitro and in vivo, we did not 
observe the same affinity based maximum expression relationship that was 
observed with IRF4 (Figure 3.2A).  
In contrast to Nur77-GFP, examination of CD25, the IL-2 receptor alpha 
chain, showed a pattern resembling IRF4, in that maximum expression levels of 
CD25 were proportional to peptide potency (Figure 3.2B).  The graded 
expression of CD25 was even more pronounced over time with large differences 
observed at 48h post-stimulation. Eomesodermin (Eomes), a transcription factor 
associated with memory CD8 T cells, has been shown to be downregulated by 
IRF4 (Nayar et al., 2012). Therefore, we predicted an inverse relationship 
between Eomes and IRF4 expression in stimulated OT-I T cells.  Consistent with 
this, we observed Eomes expression increasing at the low peptide doses just 
above the threshold needed to induce CD69 upregulation; as peptide doses 
increased, leading to increasing levels of IRF4, Eomes expression was reduced 
in a dose-dependent manner.  Additionally, peak expression levels of Eomes 
were inversely related to peptide potency, as the highest levels of Eomes were 
observed after stimulating OT-I cells with the weakest potency G4 peptide 
(Figure 3.2C).    These data confirm our findings that some gene expression 
responses are highly tunable by TCR signal strength, and depend on the binding 
interactions of individual MHC:peptide complexes with the TCR, and not just on 
the relative dose of antigenic peptide present on antigen-presenting-cells. 
 
  
 49 
 
Figure 3.2. Graded TCR signaling induces distinct patterns of Nur77, CD25, 
and Eomes expression. 
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Figure 3.2. Graded TCR signaling induces distinct patterns of Nur77, CD25, 
and Eomes expression. 
(A) OT-I Nur77-GFP cells were treated with varying doses of N4, T4, or G4 
peptides for 24h. Representative histograms for Nur77-GFP are shown for the T4 
peptide (left). GFP MFI is plotted for each peptide dose (middle). Cells were 
treated with 1nM N4, 100nM T4, or 1µM G4 from 12-48h and MFI for each 
peptide is plotted over time. 
(B) OT-I cells were treated with varying doses of N4, T4, or G4 peptides for 24h. 
Representative histograms of CD25 staining are shown for the T4 peptide (left). 
CD25 MFI is plotted for each peptide dose (middle). Cells were treated with 1nM 
N4, 100nM T4, or 1µM G4 from 12-48h and MFI for each peptide is plotted over 
time. 
 (C)  OT-I cells were treated with varying doses of N4, T4, or G4 peptides for 
24h. Representative histograms of Eomes intracellular staining are shown for the 
T4 peptide (left). Eomes MFI is plotted for each peptide dose (middle). Cells were 
treated with 1nM N4, 100nM T4, or 1µM G4 from 12-48h and MFI for each 
peptide is plotted over time. 
Data are representative of two to three experiments. 
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ITK	activity	drives	graded	IRF4	expression	in	CD8+	T	cells	
To address in greater detail the TCR signals responsible for graded 
expression of genes based on TCR signal strength, we chose to focus on the 
regulation of IRF4.  We reasoned that binary modes of expression, such as that 
seen for CD69, had previously been characterized.  Specifically, Das et. al. 
demonstrated a positive feed-forward pathway accounting for the all-or-nothing 
response of Cd69 to TCR stimulation. In this study, the authors showed that 
following TCR stimulation, the initial production of the second messenger DAG 
activated the Ras GTP-exchange factor Ras-GRP, leading to the generation of 
activated Ras molecules.  These Ras-GTP molecules bound to a second Ras 
GTP-exchange factor SOS, acting as an allosteric modulator of SOS activity and 
promoting a massive enhancement in the production of activated Ras.  A 
consequence of this feed-forward loop was that low signaling thresholds could 
rapidly produce maximal activation of the Ras-MAPK pathway, a key inducer of 
CD69 expression. The authors then linked this pathway to the bimodal 
expression of CD69 (Das et al., 2009). In contrast to this well-characterized 
pathway producing bimodal expression of CD69, the signals accounting for 
graded expression of IRF4 in response to variations in TCR signal strength have 
not been described.  
While changes in IRF4 expression were known to be dependent on ITK 
activity in the context of low dose αCD3 stimulation (Nayar et al., 2012), to 
pursue this connection further, we generated Itk-/- OT-I TCR transgenic mice. 
Stimulation of splenocytes from these mice with the three Ova peptide variants 
showed that CD69 upregulation was nearly unaffected by the absence of ITK 
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when T cells were stimulated with varying doses of N4 or T4 peptide.  Stimulation 
with the weakest potency peptide G4 showed a modest impairment of CD69 
upregulation, but the maximal response of CD69 expression could be restored by 
modest increases in peptide dose (Figure 3.3A).     
In contrast to CD69, IRF4 upregulation was markedly reduced in 
stimulated Itk-/- OT-I T cells, particularly in response to T4 and G4 peptides 
(Figure 3.3B-C).  Interestingly, the overall peptide concentration-dependence of 
IRF4 expression was not changed; for example, for T4 peptide, the EC50 for WT 
OT-I cells was 1.3nM and was 1.0nM for Itk-/- cells.  However, the maximum level 
of IRF4 expression was significantly decreased, in addition to being substantially 
delayed (Figure 3.3D-E).  To further explore the relationship between ITK and 
maximum IRF4 expression, we treated OT-I cells with a small molecule ITK 
inhibitor PRN-694 (Zhong et al., 2015).  Inhibition of ITK significantly reduced 
IRF4 expression in WT OT-I cells stimulated with either N4 or T4 stimulated 
peptide, with similar IC50s (20-40nM) (Figure 3.3F). Further evidence that ITK 
activity could fine tune IRF4 expression was generated in an additional 
experiment, where cells were treated with multiple doses of T4 peptide, and for 
each peptide dose, cells were treated with a series of doses of PRN-694 in an 
8x8 matrix format (Figure 3.3G).  Quantification of these dose-response 
experiments demonstrates a clear relationship between ITK activity and 
maximum IRF4 expression, as is evident by the stratified plateaus of the dose 
response curves. PRN694 also inhibited CD25 expression at a similar potency as 
for inhibition of IRF4 upregulation, but did not inhibit CD69 or Nur77-GFP 
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expression (Figure 3.3H).  Overall, these studies demonstrated that modulation 
of TCR signal strength by reducing TCR affinity for MHC:peptide or by inhibiting 
ITK activity led to reduced IRF4 expression.  Furthermore, these data also 
showed that low affinity peptides were unable to induce the same levels of IRF4 
expression as higher affinity peptides, regardless of the dose of peptide provided.      
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Figure 3.3. ITK inhibition reduces maximum IRF4 expression in CD8+ T cells 
in a graded manner. 
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Figure 3.3. ITK inhibition reduces maximum IRF4 expression in CD8+ T cells 
in a graded manner. 
(A-B) OT-I WT (Itk+/+) or OT-I Itk-/- (Itk-/-) T cells were stimulated each peptide for 
24h at multiple doses. %CD69+ (A) and IRF4 MFI (B) are plotted for each 
peptide concentration. 
(C) Representative histograms of IRF4 intracellular staining for 1nM N4, 100nM 
T4, and 1µM G4 peptide stimulations of Itk+/+ or Itk-/- cells.  
(D) Itk+/+ or Itk-/- OT-I cells were stimulated with 100nM T4 peptide at timepoints 
from 12-48h, and IRF4 MFI is plotted.  
(E) IRF4 MFI values of Itk+/+ or Itk-/- cells stimulated with 100nM T4 for 24h. **** 
p≤0.0001 (unpaired student t test) 
(F) OT-I T cells were stimulated with 1nM N4 and 100nM T4 peptide while 
simultaneously treated with varying doses of the ITK inhibitor PRN694 for 24h.  
Cells were stained for intracellular IRF4 and MFI of IRF4 staining under each 
condition is displayed.   
(G) OT-I T cells were stimulated with a range of doses of T4 peptide in a matrix 
using varying doses of PRN694.  After 24h the cells were stained for IRF4, and 
the IRF4 MFI for each condition is displayed.  Each curve represents a dose 
response of T4 peptide at a single concentration of PRN694.  
(H) OT-I T cells were stimulated with 100nM T4 peptide with varying doses of 
PRN694 for 24h. The cells were stained for IRF4, CD69, and CD25. For Nur77, 
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the Nur77-GFP reporter was used. The MFI values were normalized to a positive 
and negative control to obtain % Inhibition.  
Data are representative of three to five experiments.  
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Calcium	signaling	drives	graded	IRF4	expression	in	CD8+	T	cells	
To determine the component(s) of TCR signaling that could account for 
the graded expression of IRF4 in response to variable TCR signaling, as well as 
the importance of ITK signaling in this response, we considered the major 
transcription factors activated by the TCR.  Due to the demonstrated role of ITK 
in this phenomenon, we focused on pathways downstream of PLC-γ1, the 
MAPK, NF-κB, and calcium/NFAT signaling pathways (Brownlie and Zamoyska, 
2013) (Macian, 2005; Paul and Schaefer, 2013). As previous studies have 
demonstrated that Itk-/- T cells have a substantial defect in calcium signaling 
amplitude (Miller et al., 2004) (Donnadieu et al., 2001), we initially hypothesized 
that calcium could directly contribute to graded IRF4 expression in T cells.  
To address the signaling pathways that could be contributing to increased 
IRF4 expression, we utilized two common pharmacological agents commonly 
used to stimulate T cells in vitro, phorbol 12-myristate 13-acetate (PMA) and 
Ionomycin. PMA is a small molecule mimetic of DAG that directly activates 
protein kinase C and Ras-MAPK signaling, whereas the calcium ionophore, 
Ionomycin, induces calcium signaling in T cells.  Unlike the usual strategy of 
combining these two agents together to stimulate T cells, we separately treated 
WT OT-I cells with varying doses of PMA or Ionomycin alone.  After 24h, IRF4 
expression was assessed by flow cytometry (Figure 3.4A). After treatment with 
PMA, we observed a binary response of IRF4 expression, with a modest 
induction of IRF4 that achieved a stable plateau.  In contrast, treatment with 
Ionomycin recapitulated the graded induction of IRF4 expression. Only in 
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combination do the two agents yield comparable IRF4 expression to that 
observed with strong peptide antigen-dependent stimulation (Figure 3.4B). 
Furthermore, the ability of Ionomycin to promote a graded induction of gene 
expression was unique to IRF4, as neither CD69, Nur77-GFP, nor CD25 showed 
a comparable upregulation induced by calcium signaling alone (Figure 3.5A-C).  
The calcineurin inhibitor FK-506 was also able to block IRF4 upregulation, 
emphasizing the dependence of this response on calcium signaling (Figure 
3.4C).  These data indicated that IRF4 is regulated by multiple signaling 
pathways, but that the calcium pathway is responsible for the graded expression 
of IRF4 in response to variations in TCR signal strength.   
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Figure 3.4. Multiple signaling inputs drive IRF4 expression with calcium 
signaling controlling graded expression. 
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Figure 3.4. Multiple signaling inputs drive IRF4 expression with calcium 
signaling controlling graded expression. 
(A) OT-I T cells were treated with varying doses of PMA or Ionomycin for 24h, 
and cells were stained for intracellular IRF4. Representative histograms of IRF4 
staining are shown. 
(B) Representative histograms of IRF4 staining for OT-I cells left unstimulated 
(Naïve), or stimulated with 500ng/mL Ionomycin, 10ng/mL PMA, a combination of 
both, or 1nM N4 for 24h.  
(C) Representative histograms of IRF4 staining for OT-I cells treated with 100nM 
T4 for timepoints from 2-16h in the absence (left) or presence of 100nM FK506.  
Data are representative of three to five experiments. 
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Figure 3.5. PMA and Ionomycin together drive graded IRF4 expression 
while Nur77 and CD69 show modest expression with PMA alone. 
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Figure 3.5. PMA and Ionomycin together drive graded IRF4 expression 
while Nur77 and CD69 show modest expression with PMA alone. 
(A) Representative heat map of IRF4 MFI values for OT-I T cells treated with 
various doses of PMA and Ionomycin in combination for 24h. 
(B-D) Representative histograms for CD69 (B), Nur77-GFP (C), and CD25 (D) 
after treatment with PMA or Ionomycin for 24h. 
Data are representative of two to three experiments. 
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Reducing	TCR	signal	strength	digitally	regulates	NFAT	activation,	a	transcription	factor	
that	binds	to	the	Irf4	promoter		
We hypothesized that the calcium-mediated regulation of IRF4 expression 
worked through NFAT activation. NFAT is a family of transcription factors that are 
regulated indirectly by calcium flux through the removal of inhibitory 
phosphorylation sites by the calcium-activated phosphatase calcineurin 
(Dolmetsch et al., 1998; Marangoni et al., 2013). Normally, NFAT is highly 
phosphorylated and sequestered in the cytoplasm. When calcineurin is active, 
these sites are removed, unmasking the nuclear localization domain and allowing 
nuclear transport where it can then bind to DNA along with other transcription 
factor binding partners, often AP-1 (Hogan et al., 2003; Müller and Rao, 2010). 
To test the effects of graded TCR signaling on NFAT activation in CD8 T cells, 
we utilized a nuclear flow cytometry assay to assess nuclear NFAT levels in 
activated OT-I T cells (Gallagher et al., 2018). For these experiments, OT-I CD8+ 
T cells were isolated, labeled with fluorescent cell tracking dye, and then mixed 
with unlabeled splenocytes plus varying doses of the three peptide antigens.  
After 30 minutes, nuclei were prepared and stained with an antibody to NFAT1.  
Histograms of NFAT1 staining in nuclei of OT-I cells stimulated with varying 
concentrations of the T4 peptide variant showed that NFAT1 activation was not 
graded in nature, but rather, exhibited a binary response (Figure 3.6A, left panel).  
As the dose of peptide increased, the proportion of OT-I cells with nuclear 
NFAT1 increased in a dose-dependent manner (Figure 3.6A, right panel).  While 
NFAT activation was binary at the single-cell level, the overall pattern of NFAT1 
activation seen in the population of OT-I cells as a whole reflected both the dose 
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of peptide as well as the binding strength of each peptide variant.  When plotted 
as a percentage of NFAT1+ nuclei, the data for NFAT1 activation show a striking 
similarity to the data examining IRF4 protein expression under these same 
conditions. Thus, at this early 30 minute timepoint, the OT-I population shows a 
maximum level of NFAT1-positive nuclei that is proportional to peptide affinity 
with N4>T4>G4.  
We then examined the effect of ITK activity on NFAT activation. As shown 
in Figure 3.6B (left panel), ITK inhibition by PRN694 retained a bimodal response 
of NFAT1 activation following stimulation of OT-I cells with antigen-presenting-
cells and peptide.  Instead, inhibition of ITK reduced the percentage of NFAT1+ 
nuclei at each peptide dose tested (Figure 3.6B). These results also mirror the 
effects of ITK deficiency on the expression of IRF4 protein in response to varying 
doses of T4 peptide.  To generate a more detailed view of the NFAT1 activation 
response, we performed a timecourse experiment, including timepoints ranging 
from 5 minutes to 60 minutes post-stimulation.   These data confirmed our initial 
observations that varying TCR signal strength had a dramatic effect on the 
kinetics of NFAT1 nuclear localization (Figure 3.6C).  Whereas higher doses of 
N4 peptide elicited a more rapid rise in the percentage of NFAT1+ nuclei, 
stimulation with lower doses of this peptide delayed the accumulation of NFAT1+ 
nuclei.  Strikingly, the weaker peptide variant T4 was unable to induce NFAT1 
nuclear localization in any cells, regardless of the peptide dose, within the first 15 
minutes of stimulation (Figure 3.6C, right panel).  This lag in NFAT nuclear 
localization is consistent with the delay in calcium flux onset observed in single 
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OT-I cells stimulated with lower doses of the N4 peptide antigen (Dura et al., 
1AD). We reasoned that this delay in NFAT activation could dictate the graded 
levels of IRF4 protein seen at later timepoints.  Extensive characterization of 
NFAT DNA binding sites in activated CD8+ T cells has been reported by A. Rao 
and colleagues (Martinez et al., 2015a). Analysis of these published data for 
NFAT binding sites at the Irf4 promoter region revealed a robust peak 1.2kB 
upstream of exon 1 (Figure 3.6D).  Interestingly, this NFAT binding peak is 
present in cells that expressed an NFAT protein carrying amino acid substitutions 
that interfere with its binding to AP-1.  These data confirm that NFAT is able to 
bind to the Irf4 regulatory region as a homodimer in the absence of its usual 
binding partner, consistent with its robust control through calcium signaling alone.  
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Figure 3.6. Reducing TCR signal strength digitally regulates activation of 
NFAT, a transcription factor that binds to the Irf4 promoter. 
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Figure 3.6. Reducing TCR signal strength digitally regulates activation of 
NFAT, a transcription factor that binds to the Irf4 promoter. 
(A) Representative histograms of NFAT1 fluorescence in OT-I nuclei isolated 
after T cells were stimulated with B6 splenocytes pulsed with indicated doses of 
T4 peptide for 30m (left). Line plots of %NFAT+ nuclei after 30m of stimulation 
with B6 splenocytes pulsed with indicated doses of either N4, T4 and G4 
peptides (right). OT-I nuclei were identified as CellTrace Violet+ events. 
(B) Representative histograms of NFAT1 fluorescence in OT-I nuclei after cells 
were stimulated for 30m with B6 splenocytes pulsed with 25 nM T4 peptide with 
or without 50nM PRN694 treatment (left). Line plots of %NFAT+ (nuclear NFAT) 
values are shown for the T4 peptide dose response with and without 50nM 
PRN694 treatment (right). Nuclei were gated on CellTrace Violet+ events. 
(C) Line plots of %NFAT+ OT-I nuclei over a 60m timecourse after cells were 
stimulated B6 splenocytes pulsed with varying doses of either N4 (left) or T4 
(right) peptides as indicated.  
(D) NFAT1 ChIP-Seq data (GSE64409) on activated CD8 T cells from Martinez 
et al (Martinez et al., 2015b) were visualized using IGV software and a snapshot 
was taken of the Irf4 locus. The data represents 4 samples: (1) WT T cells, 
transduced with Mock construct, unstimulated (2) Nfatc1-/- T cells, transduced 
with Mock construct, stimulated with PMA/Ionomycin for 1h (3) Nfatc1-/- T cells, 
transduced with CA-RIT-NFAT (constitutively active NFAT unable to bind AP-1), 
stimulated with PMA/Ionomycin for 1h (4) WT T cells, transduced with Mock 
construct, stimulated with PMA/Ionomycin for 1h. 
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Data are representative of two or three experiments (A-C).   
 69 
Graded	TCR	signaling	alters	the	kinetics	of	Irf4	mRNA	upregulation	
 IRF4 upregulation is detectable by 6h post-stimulation and generally 
peaks at 24h, with maximum levels of expression differing between T cells 
stimulated by ligands of different potencies.  These data suggested that 
evaluating the kinetics of early Irf4 mRNA upregulation could be informative in 
understanding how cells stimulated with distinct TCR signal strengths ultimately 
accumulate different amounts of IRF4 protein.   Using RNA flow cytometry, we 
measured Irf4 mRNA in activated OT-I T cells over the first 16h post-stimulation.  
Cells stimulated with 100nM of T4 peptide rapidly upregulated Irf4 mRNA by 2h, 
and levels of this mRNA were relatively constant for 16h post-stimulation (Figure 
3.7A-B).  We also observed a sharp transition of cells going from Irf4 mRNA 
negative to positive in the time from 0-2h post-stimulation.  Consistent with the 
IRF4 protein data, FK506 completely blocks upregulation of Irf4 mRNA. These 
findings emphasize the important role of calcium signaling and NFAT activation 
in Irf4 mRNA transcription, a result consistent with previous data demonstrating 
NFAT binding to the Irf4 gene locus in activated T cells (Man et al., 2017). 
In contrast, inhibition of ITK signaling by treatment of cells with PRN694 
delayed, but did not abolish, the upregulation of Irf4 mRNA.  Similar to our results 
examining NFAT activation, we observed two distinct populations of OT-I cells at 
2h post-stimulation in the presence of PRN694, one population positive for the 
Irf4 mRNA and one population remaining negative.  Compared to the cells 
stimulated in the absence of the ITK inhibitor, those treated with PRN694 showed 
a slower transition to having Irf4 mRNA, along with a broader histogram peak, 
indicative of greater variability in expression within the population. The role for 
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ITK in accelerating the rate of Irf4 mRNA upregulation was also confirmed by 
examination of stimulated WT versus Itk-/- OT-I T cells.  Again, along with 
delayed kinetics of Irf4 mRNA expression in the absence of ITK, we observed a 
bimodal pattern of Irf4 mRNA staining (Figure 3.7C). Finally, as expected based 
on the protein expression data, we found no major effect on Cd69 mRNA 
expression in the absence of ITK (Figure 3.7C).  
Reduced TCR signaling consistently yielded a reduction in peak 
expression of IRF4 protein, based on the IRF4 histogram MFI, while also 
showing a broader distribution within the population, with a broader histogram 
peak observed in ITK-inhibited T cells. We wanted to measure this increase in 
histogram width. To quantify this variability in expression we plotted the 
coefficient of variance (CV) for IRF4 MFI of OT-I cells stimulated with 100nM T4 
peptide, in the absence or the presence of varying different doses of PRN694 
(Figure 3.7D).  ITK inhibition significantly increased the CV of both IRF4 protein 
and Irf4 mRNA, suggesting increased heterogeneity of expression across the 
clonal population.  This was not a consequence of failing to activate a subset of 
cells, as >95% of cells were CD69+ under each of these conditions.  
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Figure 3.7. Reducing TCR strength, through ITK inhibition, delays Irf4 
mRNA upregulation and increases variability across the population. 
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Figure 3.7. Reducing TCR strength, through ITK inhibition, delays Irf4 
mRNA upregulation and increases variability across the population. 
(A-B) OT-I T cells were treated with 100nM T4 peptide for timepoints from 2-16h 
either alone or in the presence of 100nM PRN694 or 100nM FK506. (A) 
Representative histogram plots of Irf4 mRNA expression.  (B) Data are plotted as 
%Irf4 mRNA positive (left) or as Irf4 mRNA MFI (right) over time.  
(C) Itk+/+ or Itk-/- cells OT-I T cells were treated with 100nM T4 peptide for 2 or 6h. 
Representative histograms for Irf4 and Cd69 mRNA expression ar shown.  
(D) Representative histograms for OT-I T cells stimulated with 100nM T4 peptide 
in the absence or presence of various doses of PRN694 treatment for 24h, and 
cells were stained for intracellular IRF4.  The coefficient of variance (CV) of IRF4 
staining was plotted for each treatment group. * p≤0.1 ** p≤0.01 *** p≤0.001 **** 
p≤0.0001 (one-way ANOVA followed by Dunnett’s test for the left panel and 
unpaired student t test for the right panel) 
Data are representative of two to three experiments. 
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Discussion	
 Understanding the molecular mechanisms that control graded signaling 
through the TCR has been a central effort in T cell biology. A component of this 
effort has been studies directed at elucidating the contribution of the Tec kinase 
ITK to this process. Here, we utilized a combination of assays providing single 
cell data to dissect the signaling inputs that control the graded expression of the 
transcription factor IRF4, a key factor regulating the magnitude of the CD8+ 
effector T cell response to infection.   Our studies revealed a process in which a 
clonal population of naïve CD8 T cells integrated different strengths of TCR 
stimulation into binary NFAT1 activation responses.  Weaker TCR stimulation led 
to a delay in the kinetics of NFAT nuclear localization that correlated with slower 
upregulation of Irf4 mRNA, ultimately resulting in reduced expression of the IRF4 
protein.  As a consequence of this mechanism, a population of CD8+ T cells that 
receives weak TCR signaling is destined to undergo limited clonal expansion 
(Man et al., 2013; Nayar et al., 2015; 2014; Yao et al., 2013). 
 Our results are in agreement with the recent studies of Richard et. al. 
Using state-of-the-art single cell RNA sequencing and proteomic techniques, the 
authors showed that the strength of TCR signaling controlled the rate at which 
individual cells were activated within a clonal population (Richard et al., 2018), 
and was responsible for greater variability in gene expression between individual 
cells in low affinity clonal populations. However, in analyses of cytolytic effector 
functions several days post-stimulation, this delay in kinetics among weakly 
stimulated naïve CD8+ T cells did not ultimately impair their cytolytic capacity, 
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results that are in line with our observations that only some genes (e.g., Irf4, 
Il2ra) are sensitive to this delay in activation and are likely driving the magnitude 
of clonal expansion, while others (e.g., Cd69) are not.  
 Our results also expand our knowledge of how the Tec kinase ITK 
regulates the strength of TCR signaling. Many studies have documented that ITK 
is not required for T cell activation per se. Instead, T cells lacking ITK have 
selective defects in some T cell responses, while other responses appear 
unaffected by the absence of ITK.  For instance, naïve Itk-/- CD4 T cells are 
defective in producing IL-17A or IL-9, when stimulated under TH17 or TH9 
polarizing conditions, respectively (Gomez-Rodriguez et al., 2016; 2014). Yet, Itk-
/- mice are proficient at clearing infections of Leishmania major, and viruses such 
as LCMV, Influenza A, and Vaccinia, responses that require effective TH1 and 
cytotoxic CD8+ T cell responses, respectively (Atherly et al., 2006a; 2006b; 
Bachmann et al., 1997; Schaeffer et al., 2001).  Interestingly, these data also 
correspond nicely to the recent findings of Richard, et al, which found that 
expression of genes required for cytotoxic T cell function were independent of the 
strength of the initial T cell stimulation.  
Our studies indicate that ITK functions as an accelerator in the TCR 
signaling pathway.  In this regard, ITK is not required for TCR signaling, but acts 
to accelerate the process by which TCR stimulation produces a calcium 
response capable of inducing NFAT nuclear translocation.  We speculate that 
ITK functions to increase the number of activated PLC-γ1 molecules produced by 
each stimulated TCR.  As our data also show that NFAT nuclear translocation is 
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an all-or-nothing response to TCR stimulation, we envision a sharp threshold of 
IP3 production by activated PLC-γ1 that is required to induce NFAT activation.  
When ITK signaling is engaged, the rate at which this threshold is achieved can 
be dramatically increased.  It is likely that other key transcription factors activated 
by TCR stimulation have alternative modes of response to variations in TCR 
signal strength, possibly explaining why some genes expression responses, but 
not all, are sensitive to ITK signaling. 
 Our data indicate that NFAT is not the sole transcription factor contributing 
to IRF4 expression after TCR stimulation.  As shown by the modest upregulation 
of IRF4 in response to PMA alone, as well as the combinatorial effect of PMA 
and Ionomycin added together, we conclude that additional DAG-dependent 
factors are required for optimal IRF4 upregulation in response to TCR signaling.  
One likely pathway contributing to the NFAT-independent component of IRF4 
expression is NF-κB, as previous studies have suggested a role for both 
canonical NF-κB p65, as well as c-Rel in Irf4 expression (Grumont and 
Gerondakis, 2000). While these findings reveal the complex and multifactorial 
regulation of genes induced by TCR stimulation, they also highlight the utility of 
reductionist experiments, such as those described here, in identifying key inputs 
responsible for differing responses to variations in TCR signal strength.  Our 
studies also demonstrate that increasing ligand dose or density on antigen-
presenting-cells cannot necessarily overcome signaling deficits due to weakly 
stimulatory ligands.    Thus, increasing the concentration of weakly potent 
peptide antigens is unable to generate the levels of IRF4 in naïve CD8+ T cells 
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that can be achieved by more potent ligands. Understanding the complete 
program of genes that share this characteristic of Irf4 will provide critical 
information in the development of improved vaccines and T cells used for 
adoptive immunotherapy, to maximize desired effector and/or memory T cell 
responses.   
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Introduction	
 During the adaptive immune response, activated lymphocytes migrate 
from the secondary lymphoid organs to the site of infection to prevent further 
expansion of the invading pathogen. A complex network of cytokine and 
chemokine signaling gradients guide these cells to the damaged area, aided by 
the innate immune response, which uses pathogen-associated molecular 
patterns (PAMPs) to activate resident myeloid cells to secrete these factors. 
These soluble proteins act on the resident endothelial cells causing them to 
produce a variety of adhesion molecules, facilitating recruitment of the circulating 
lymphocytes. The multi-step process where lymphocytes are recruited from the 
vasculature to the inflamed tissue, transendothelial migration (TEM), is a critical 
step in the immune response. First, the lymphocytes are captured and bound to 
the apical endothelial surface, controlled by selectin interactions, allowing the cell 
to “roll” along the membrane while resisting the shearing force of the blood. 
Tighter integrin-based interactions follow, causing the cell to arrest and “crawl” 
along the endothelial cell searching for junctions between cells. Then through 
diapedesis, the lymphocyte migrates from the blood vessel lumen to the 
connective tissue (Vestweber, 2015).  
 In the context of autoimmune disease, autoreactive T cells that are 
activated and expanded in the secondary lymphoid organs, require TEM to enter 
target organ tissue in the absence of pathogen-associated inflammatory cues 
that normally facilitate extravasation. While the signaling requirements for 
autoreactive T cell migration are not completely understood, there is evidence 
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that signaling through both the T cell receptor (TCR) and costimulatory molecules 
(i.e. CD28) are playing a role. In mice lacking the tolerance ligand cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4), a robust expansion of autoreactive T 
cells is observed, leading to multiple organ damage and death of the mice within 
4 weeks (Chambers et al., 1997; Ise et al., 2009). When the Ctla4-/- mice were 
crossed to a knockout of Inducible T cell Kinase (ITK) (Itk-/-), a tyrosine kinase 
important in TCR signal transduction (Andreotti et al., 2018; Berg et al., 2005; 
Conley et al., 2016), the disease pathology was completely prevented (Jain et al., 
2013). However, the T cells in the double knockout mice remained autoreactive, 
had a highly activated phenotype and expanded to large numbers in secondary 
lymphoid organs and blood. Two-photon imaging showed impaired interactions of 
Ctla4-/-Itk-/- T cells with lung endothelial cells after adoptive transfer into naïve 
wild-type recipients.  These data suggested a requirement for robust TCR 
signaling to prime autoreactive T cells for effective TEM. This requirement for ITK 
is not observed in the context of infection, as Itk-deficient T cells are able to clear 
infections in tissue restricted models like Influenza A (Fan et al., 2012). 
Furthermore, the importance of strong TCR signaling for the development of 
pathogenic autoreactive tissue-infiltrating T cells was also observed in a study 
using the RIP-mOVA mouse, where ovalbumin antigen is expressed in the 
pancreas.  In this study, CD8 T cell-mediated induction of diabetes was only 
seen in mice that were adoptively transferred with ovalbumin-specific (OT-I TCR 
transgenic) T cells stimulated with high-affinity peptide antigen, a process that 
was dependent on the integrin VLA-4 (King et al., 2012).  
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 The process of TEM requires a number of cell surface receptors that 
facilitate intercellular contact as well as intracellular signal transduction. In T cell 
TEM, P-selectin (and E-selectin) from the endothelium binds P-selectin 
glycoprotein ligand-1 (PSGL1) and CD44 on the activated lymphocyte promoting 
the “rolling” process. Then, integrins such as intercellular adhesion molecule 1 
(ICAM1 and VCAM1) bind to ligands, lymphocyte function-associated antigen 1 
(LFA1 and VLA-4), on the T cell.  Integrin binding is a stronger interaction 
compared to that of the selectins for their ligands, leading to T cell “crawling” on 
the endothelium and later diapedesis (Hogg et al., 2011; McEver and Zhu, 2010; 
Zarbock et al., 2011). In the lymph node, T cells upregulate CD44 expression 
after antigen stimulation. Naïve T cells constitutively express PSGL1, however, 
after stimulation, they modify the receptor by adding carbohydrate molecules to 
the extracellular portion of the receptor. This post-translational modification 
increases the binding of PSGL1 for its cognate ligand P-selectin (McEver and 
Cummings, 1997; Norman et al., 1995) Both PSGL1 and CD44 function in the 
rolling stage of TEM.  
The glycoprotein, T cell immunoglobulin and mucin domain 1 (TIM-1), is 
another P-selectin ligand. Largely expressed in activated TH1 and TH17 cells, the 
receptor mediates trafficking in multiple infection and autoimmune models 
(Angiari et al., 2014). Activated T cells also express the integrin LFA1, which is 
critical for the crawling process (Hogg et al., 2011; Walling and Kim, 2018). The 
costimulatory ligand DNAX accessory molecule 1 (DNAM-1, CD226), while 
normally associated with T and NK cell cytotoxicity (Gilfillan et al., 2008; Welch et 
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al., 2012), has also been linked to autoreactive T cell function (Ayano et al., 
2015). Blocking of CD226 signaling with an antibody inhibited TH1 expansion and 
tissue pathology in a mouse model of autoimmunity, experimental autoimmune 
encephalomyelitis (EAE) (Dardalhon et al., 2005).   
The upregulation of these surface receptors on T cells is predominantly 
mediated by TCR signaling following antigen encounter. TCR signaling also 
modulates LFA1 function at multiple levels (Beinke et al., 2010). For example, 
one of the critical steps for strong binding of LFA1 to its ligand ICAM-1 is the 
TCR-mediated signal that promotes a conformational change in LFA1, converting 
its extracellular domain from the bent to the extended conformation. In addition to 
TCR signaling, this change can also be triggered by signaling through some 
chemokine receptors (GPCRs) or by P-selectin binding. However, TCR signaling 
likely also contributes to LFA1 function by mechanisms other than the signal-
induced conformational change in the LFA1 extracellular domain.  Vesicular 
trafficking of LFA1 to the plasma membrane is dependent on the small GTPase 
RAP1.  RAP1 is activated by a family of GEFs, one of which, CALDAG-GEF1, is 
regulated by phospholipase C (PLC), a lipase central in TCR signaling that 
cleaves plasma membrane-associated phospholipid PIP2 into diacylglycerol 
(DAG) and inositol triphosphate (IP3) (Ghandour et al., 2007; Katagiri et al., 
2004). PLCγ is the target of ITK, suggesting that ITK could play a role in this 
process. Indeed, Itk-/- T cells are defective in LFA1-mediated adhesion and TH1 
and TH17 cells treated with a small molecule ITK inhibitor (PRN694) have 
impaired P-selectin binding compared to control T cells. (Cho et al., 2015; 
 82 
Finkelstein et al., 2005; Zhong et al., 2015). Upstream TCR signaling molecules 
Lck, ZAP70, and SLP-76 are also associated with integrin signaling (Baker et al., 
2009; Nika et al., 2010).  
 Using the OT-I TCR transgenic mouse line, in which CD8+ T cells express 
a TCR specific for the chicken ovalbumin peptide SIINFEKL, we investigated the 
role of TCR signal strength on adhesion and migration molecule expression, and 
on autoreactive T cell tissue infiltration.  To vary TCR signal strength, we took 
advantage of the altered peptide ligands (APLs) identified for the OT-I TCR 
(Zehn et al., 2009).  Additionally, we addressed the contribution of ITK signaling 
to the optimal expression of adhesion molecules and T cell migration in vivo.  We 
found that, similar to our previous observations with CD4+ T cells, CD8+ T cells 
depend on ITK activity for robust selectin binding and autoreactive T cell 
migration. We also found that high expression of multiple receptors contributing 
to TEM, including modified PSGL1, CD44, and CD226 require CD28 
costimulation along with strong TCR signaling, indicating that TCR and CD28 
signaling pathways cooperate to induce maximal expression of these genes.  
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Results	
Reduced	TCR	signaling	inhibits	selectin	ligand	expression	and	function	in	CD8+	T	cells		
In the first 24-48h after TCR stimulation, CD8+ T cells upregulate a variety 
of proteins that play key roles in T cell trafficking. One factor, CD44, is increased 
and remains stable. Another factor, PSGL1, is post-translationally modified with 
carbohydrate molecules to increase its ability to bind P-selectin. Here, we used 
the TCR transgenic model OT-I to study CD8+ T cell activation in response to 
different peptide ligands that stimulate this TCR with differing potencies. The 
cognate peptide for the OT-I TCR is derived from chicken Ovalbumin, with the 
amino acid sequence of SIINFEKL (N4) (Hogquist et al., 1994). By substituting 
amino acids at the fourth position, TCR affinity can be decreased without 
affecting MHC Class I binding (Zehn et al., 2009). The SIITFEKL (T4) peptide is 
approximately 100-fold less potent, and SIIGFEKL (G4) is approximately 1000-
fold less potent, than N4 (Rosette et al., 2001; Zehn et al., 2009) 
Initially, we performed a simple experiment in which each of the three 
peptides were added to bulk splenocytes, acting as antigen presenting cells 
(APCs) then combined with CD8+ T cells purified from the spleens of OT-I TCR 
transgenic x Rag2-/- (hereafter referred to as OT-I) mice. The T cells were 
stimulated for 48h and analyzed for P-selectin binding. Because PSGL1 
modification, not expression, is central to its function, we used a purified form of 
P-selectin, which is fused to the Fc region of human IgG1, allowing for detection 
with a fluorescently conjugated secondary antibody. After 48h, the cells were 
stained with the recombinant protein and assessed by flow cytometry as an 
assay for PSGL1 binding.  At doses of peptide capable of inducing maximum 
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CD69 expression (Figure 4.1A, left panel), all three peptides bound P-selectin, 
with their histograms greater than observed in naïve cells. However, the T4 
stimulated cells had a large subpopulation, which bound more P-selectin (Figure 
4.1A, right panel). This subpopulation likely expresses the glycosylated form of 
PSGL1 and was present to a lesser extent in G4 and N4 stimulated cells. It is 
unclear how kinetically stable this population is and if the high-affinity N4 
stimulation condition yields the same population earlier in the response that 
degrades over time.  
We next examined if this high affinity P-selectin population was sensitive 
to ITK inhibition by treating the T4 stimulated cells simultaneously with the small 
molecule inhibitor of ITK, PRN694 (Zhong et al., 2015). Reducing TCR signal 
strength with ITK inhibition blocked the generation of the high P-selectin binding 
T cells. (Figure 4.1B) This suggested that the modified PSGL1 ligand was 
dependent on the strength of TCR signaling.  
 To determine if the alternate ligand, CD44, for P-selectin was also 
sensitive to changes in TCR signal strength, we stimulated OT-I T cells with  
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Figure 4.1. Medium affinity TCR stimulation generates high P-selectin 
binding and CD44hi T cells, a subpopulation dependent on ITK activity. 
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Figure 4.1. Medium affinity TCR stimulation generates high P-selectin 
binding and CD44hi T cells, a subpopulation dependent on ITK activity. 
(A) Representative histogram plots of CD69 staining (left) and P-selectin binding 
(right) on OT-I cells stimulated with 1nM N4, 100nM T4, and 1µM G4 peptide for 
48h. Cells were stained with recombinant P-selectin-human IgG fusion protein as 
an assay for PSGL1 binding.  
(B) Representative histogram plots of P-selectin binding in OT-I cells stimulated 
with T4 peptide with and without 100nM PRN694 for 48h.  
(C) Representative histogram plots of CD44 staining in OT-I cells stimulated with 
different doses of T4 peptide for 48h.  
(D) Representative histogram plots of CD44 (left) and CD69 (right) staining in 
OT-I cells stimulated with T4 peptide with and without 100nM PRN694 for 48h.  
Cells were gated on live CD8+ TCRβ+. Data are representative of two to three 
experiments.  
  
 87 
multiple concentrations of the T4 peptide. Consistent with CD69 upregulation, 
CD44 was also increased in the T cells after 48h. (Figure 4.1C) CD44 expression 
was also sensitive to ITK inhibition, with a decrease in MFI observed in the 
PRN694 treated cells. (Figure 4.1D, left panel) While there seems to be a 
bimodal response with CD44- cells transitioning to CD44+ cells with increasing 
antigen dose, the ITK inhibited cells show a unique effect where a portion of the 
population does not turn on CD44 while the rest expresses lower amounts with 
higher variability among the CD44+ population. However, these cells were all 
able to make CD69. (Figure 4.1D, right panel) This is consistent with the 
variability we observed in IRF4 expression in T cells treated with PRN694. 
(Chapter 3) We also tested the ITK-dependence on TIM-1 activation, another 
ligand for P-selectin expressed on T cells (Angiari et al., 2014). In CD4+ T cells 
stimulated with αCD3/CD28 for 72h, PRN694 inhibited TIM-1 surface expression. 
Interestingly, TIM-1 surface expression was sensitive to calcium signaling, with a 
large increase in surface expression observed after Ionomycin treatment. 
(Hyoung-Soo Cho, unpublished) These data confirm our hypothesis that reduced 
TCR signaling, whether through lower affinity antigen or ITK inhibition, inhibits 
the T cells ability to adhere to the endothelium through P-selectin binding, the 
first critical step in TEM.    
TCR	and	CD28	costimulation	additively	drive	selectin	binding	and	effector	function	in	
CD8+	T	cells	
 We next wanted to determine the contribution of CD28 costimulation on 
the TCR-mediated selectin binding regulation. To test this we used splenocytes 
isolated from Cd80-/-Cd86-/- mice (hereafter referred to as B7-/-) as APCs. We 
 88 
were able to directly compare T cells with and without Itk stimulated with APCs 
with and without B7, the ligand for CD28. While minimal inhibition of the highly 
bound P-selectin T cells was observed with CD28 inhibition alone, a large defect 
in the Itk-/- T cells is seen, consistent with the PRN694 data. Reduction of both 
TCR and CD28 signaling further blocked this population, suggesting an additive 
effect of the signaling pathways on P-selectin binding. (Figure 4.2A, left panel) 
Similar to IRF4, this effect of P-selectin binding inhibition is independent of the 
cells ability to upregulate CD69. (Figure 4.2A, right panel) The additive effect was 
even more pronounced with CD44 expression. (Figure 4.2B) Consistent with 
PRN694 data, both a reduction in the cells ability to produce CD44 and the 
amount of protein made across the population is observed. This effect is even 
greater with both TCR and CD28 signaling reduced.  
 While IRF4 has been well characterized as a TCR-dependent mediator of 
CD8+ T cell effector function (Man et al., 2013; Nayar et al., 2015; 2014; Yao et 
al., 2013), it is unclear if CD28 costimulation plays a role in its rapid upregulation 
in stimulated CD8+ T cells. Using the B7-/- APCs, we were able to look at IRF4 
expression as well as CD25, the high affinity Il-2 receptor, another factor 
sensitive to graded TCR signaling. (Figure 4.3) Here the OT-I T cells are 
stimulated with multiple doses of the three peptide antigens N4 (Figure 4.3A-B),  
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Figure 4.2. Maximum P-selectin binding and CD44hi cells require both high 
TCR and CD28 signaling in activated CD8+ T cells. 
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Figure 4.2. Maximum P-selectin binding and CD44hi cells require both high 
TCR and CD28 signaling in activated CD8+ T cells. 
(A) Representative histogram plots of P-selectin binding (left) on OT-I (WT and 
Itk-/-) cells stimulated with 100nM T4 peptide-pulsed APCs (WT and B7-/-) for 48h. 
Cells were stained with recombinant P-selectin-human IgG fusion protein as an 
assay for PSGL1 binding. Plots of CD69 versus P-selectin binding (right). 
(B) Representative histogram plots of CD44 staining on OT-I (WT and Itk-/-) cells 
stimulated with 100nM T4 peptide-pulsed APCs (WT and B7-/-) for 48h.  
Cells were gated on live CD8+ TCRβ+. Data are representative of two to three 
experiments.  
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Figure 4.3. Maximum IRF4 and CD25 expression requires both high TCR 
and CD28 signaling in activated CD8+ T cells. 
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Figure 4.3. Maximum IRF4 and CD25 expression requires both high TCR 
and CD28 signaling in activated CD8+ T cells. 
(A-F) Representative histogram plots of IRF4 (left) and CD25 (right) on OT-I (WT 
and Itk-/-) cells stimulated with peptide-pulsed APCs (WT and B7-/-) for 24h. Cells 
were gated on live CD8+ TCRβ+. Plots of MFI values for all 4 conditions are 
shown for a dose response of each peptide. (A, B) N4 (C, D) T4 (E, F) G4.  
Data are representative of two to three experiments. 
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T4 (Figure 4.3C-D), and G4 (Figure 4.3E-F). Consistent with the selectin binding 
data, we observed an additive effect with dual inhibition of ITK and CD28. With 
high affinity N4 stimulation, CD28 signaling was not required for maximum IRF4 
expression. (Figure 4.3A, left panels) Consistent with our previous observations, 
it is lower affinity antigen that requires robust ITK activity. Here we also observed 
that this is true for CD28 signaling, with very little IRF4 and CD25 upregulation 
observed in the absence of ITK and CD28 function. (Figure 4.3C-F)  
TCR	and	CD28	signaling	drive	expression	of	CD226	in	activated	CD8+	T	cells	
 We next examined if the costimulatory factor CD226 was also driven by 
the strength of TCR stimulation in a similar manner as CD44. The 
transmembrane glycoprotein is associated with T and NK cell cytotoxicity, 
however, the cognate ligands for CD226, poliovirus receptor (PVR, CD155) and 
Nectin-2 (CD112) are also expressed on the endothelium. The receptors are 
known to regulate monocyte extravasation (Reymond et al., 2004). CD226 is also 
known to associate with the integrin LFA1 and the tyrosine kinase Fyn in T cells 
suggesting a signaling role in TEM (Shibuya et al., 2003). We tested CD226 
expression in OT-I T cells stimulated with multiple doses of the T4 peptide. 
(Figure 4.4A) Similar to CD69, a bimodal response was observed with cells 
transitioning from CD226- to CD226+ at the concentration of antigen sufficient to 
activate the T cells. However, unlike CD69, CD226 is completely blocked by ITK 
inhibition, here with treatment of PRN694. (Figure 4.4B) CD226 upregulation is 
also dependent on CD28 costimulation with an additive inhibition observed with  
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Figure 4.4. Maximum CD226 expression requires both high TCR and CD28 
signaling in activated CD8+ T cells. 
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Figure 4.4. Maximum CD226 expression requires both high TCR and CD28 
signaling in activated CD8+ T cells. 
(A) Representative histogram plots of CD226 staining in OT-I cells stimulated 
with different doses of T4 peptide for 48h.  
(B) Representative histogram plots of CD226 (left) and CD69 (right) staining in 
OT-I cells stimulated with T4 peptide with and without 100nM PRN694 for 48h. 
(C) Representative histogram plots of CD226 staining on OT-I (WT and Itk-/-) 
cells stimulated with 100nM T4 peptide-pulsed APCs (WT and B7-/-) for 48h.  
Cells were gated on live CD8+ TCRβ+. Data are representative of two to three 
experiments. 
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stimulation of Itk-deficient OT-Is with APCs lacking B7. (Figure 4.4C) This data 
suggests that multiple inputs from the TCR and CD28 signaling pathways are 
likely contributing to the transcriptional regulation of pro-migratory molecules that 
are required for TEM: PSGL1, CD44, TIM-1, and CD226.  
ITK	inhibition	partially	blocks	autoreactive	CD8+	T	cell	function	in	adoptive	transfer	
model	
 We next wanted to test the ability of these CD8+ T cells to migrate in vivo 
using a model system that required T cell extravasation to a site of antigen in the 
absence of an inflammatory environment. In the RIP-mOVA mouse, the rat 
insulin promoter (RIP) drives a transgene encoding membrane bound ovalbumin 
antigen (mOVA), restricting expression mainly to the β-islet cells of the pancreas 
(Blanas et al., 1996). Through adoptive transfer, OT-I T cells can recognize their 
cognate antigen in these islet cells and target them for CD8+ T cell mediated cell 
death. The OT-I T cells can spontaneously lead to pathology, however, 
introduction of antigen in the lymphoid compartment either through immunization 
or infection rapidly accelerates the process to within 7 days (Behrens et al., 
2004). The destruction of the β-islet cells rapidly leads to Type 1 diabetes (T1D) 
in the mice, which can be monitored by measuring glucose in the urine.  
Here, we examined if Itk-/- T cells could migrate to the pancreas in the RIP-
mOVA mice and induce T1D. King et al described a sharp affinity threshold in 
this model using multiple APLs of OT-I. The T4 peptide was at the threshold with 
~25-50% of the mice getting T1D and the N4 and V4 (similar to G4) peptides 
having a response rate of 100 and 0% respectively. We hypothesized that the T4 
affinity antigen would be sensitive to ITK activity since we knew that high affinity 
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TCR stimulation was largely independent of ITK. The low affinity ligands had no 
T1D phenotype and were not useful (King et al., 2012). To confirm that the WT 
and Itk-/- OT-Is were both activated after adoptive transfer, we labeled the T cells 
with CFSE and harvested the spleens 3 days after immunization with the T4 
peptide. (Figure 4.5A-B) Both T cell populations in the spleen diluted the CFSE 
dye, indicating robust proliferation after immunization. We then determined the 
ability of WT and Itk-/- T cells to induce T1D in the mice after T4 immunization. In 
our hands, the T4 peptide at 50µg was consistently above activation threshold in 
WT OT-Is with all of the mice in the group getting T1D within 5 days, suggesting 
that the sharp threshold is likely sensitive to small changes in experimental 
conditions or environment. (Figure 4.5C) However, we did observe a threshold 
effect in the Itk-/- OT-I transfer with 50% of the mice getting T1D within 8 days. 
The other 50% did not succumb to disease out to 3 weeks. There was also a 
delay in T1D induction in the mice that did show pathology from 5 to 8 days. This 
was confirmed by histological staining of the pancreas at day 5 with mice 
receiving WT OT-I T cells showing islet cell destruction consistent with T1D, 
which was not observed in the mice receiving Itk-/- OT-Is. (Figure 4.5D) This 
delay in onset is consistent with the delay in signaling kinetics observed in vitro 
(Chapter 3) and also delay in CD8+ effector cell expansion in Itk-/- mice infected 
with LCMV(Atherly et al., 2006a).  
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Figure 4.5. ITK activity lowers the signaling threshold for autoreactive T 
cells to cause T1D in adoptive transfer model. 
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Figure 4.5. ITK activity lowers the signaling threshold for autoreactive T 
cells to cause T1D in adoptive transfer model. 
(A-B) 5.0 x 106 OT-I T cells (WT and Itk-/- CD45.1+) were labeled with CFSE and 
adoptively transferred into RIP-mOVA mice i.v., then immunized with 50µg of T4 
peptide and 25µg of LPS i.p. 24h later. 3d after stimulation, spleens were 
harvested and stained for flow cytometry. (B) Representative histogram plots of 
CFSE dilution of WT and Itk-/- OT-Is.  
(C) 5.0 x 106 OT-I T cells (WT and Itk-/- CD45.1+) were adoptively transferred into 
RIP-mOVA mice i.v., then immunized with 50µg of T4 peptide and 25µg of LPS 
i.p. 24h later. Mice were monitored daily for urine glucose levels (>1000 mg/dL 
was considered diabetic) out to 3 weeks. N=6 per group of mice.  
(D) Histology of pancreas tissue from RIP-mOVA mice adoptively transferred 
with OT-I cells (same protocol as in (C)) harvested at day 5 compared with a WT 
mouse for H&E staining. 20X images.  
Data are representative of two to three experiments. 
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Discussion	
 The mechanisms controlling autoreactive T cell extravasation, through 
transendothelial migration, are not completely understood. Here, we use a 
combination of assays to look at changes in selectin binding in single activated 
CD8+ T cells. Consistent with results previously seen in CD4+ T cells (Cho et al., 
2015), reduced TCR signaling through ITK inhibition resulted in impaired selectin 
binding. We hypothesize that this is due to blocking glycosylation of PSGL1, 
likely sensitive to changes in metabolism, a process regulated by the ITK-
dependent transcription factor IRF4 in early activated CD8+ T cells (Man et al., 
2013). However, other possible selectin ligands, CD44 and CD226 were also 
sensitive to the strength of TCR signaling. CD44 expression was unique in that it 
had both a binary and graded response to antigen dose and ITK activity. With 
antigen dose, cells transitioned from CD44- to CD44+. However with PRN694 
treatment, the cells formed two populations: CD44- and CD44lo. The cells that 
were able to produce the glycoprotein made considerably less with higher 
variability in expression observed among the cells. The reduction in maximum 
expression and increased variability is consistent with our observations of ITK-
mediated IRF4 and CD25 expression.  
 With the striking migratory defect observed in Ctla4-/-Itk-/- mice (Jain et al., 
2013), we next examined if CD28 costimulation contributed to this defect in 
selectin binding. Using bulk splenocytes from Cd80-/-Cd86-/- (B7-/-) mice as 
antigen presenting cells (APCs), we found that selectin binding depended on 
both TCR signaling and CD28 costimulation for maximum effect. This also 
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correlated with expression of CD44 and CD226. We also found that genes 
sensitive to changes in TCR affinity and ITK activity, IRF4 and CD25, were 
diminished in the absence of CD28. This isn’t entirely surprising due to the 
codependence of both signaling pathways, specifically through PI3K activation 
ensuring PIP3-mediated recruitment of the LAT signaling complex to the plasma 
membrane (Esensten et al., 2016). These results suggest that there is likely an 
overall amplification of signaling that preferentially modulates genes that are 
sensitive to changes in TCR affinity. We hypothesize that the kinetics of gene 
upregulation are modulated by CD28 in a similar fashion as the effect seen on 
IRF4 through ITK inhibition.  
 We next turned to a mouse model of autoreactive CD8+ T cell trafficking to 
test the effect of low TCR signaling on TEM in vivo. Using the RIP-mOVA 
adoptive transfer model, we compared mice that were introduced with OT-I T 
cells with and without ITK. After immunization with the low affinity T4 peptide, we 
found that mice receiving OT-I Itk-/- T cells were 50% less susceptible to T1D. 
The mice also had a delay in T1D induction from 5 to 8 days. The variation of 
T1D in the OT-I Itk-/- group is consistent with a sharp TCR signaling threshold 
previously observed in this model (King et al., 2012). We hypothesize that the 
strength of stimulation of the T4 peptide is at this threshold and genes controlling 
TEM are more sensitive to ITK activity at this dose and affinity of antigen. We 
predict that high affinity PSGL1 is dependent on this strength of signaling and 
without proper post-translational modification is unable to effectively bind to the 
endothelial cell wall and start the process of extravasation. This sensitivity is 
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likely only observed in the context of autoreactive T cells without an inflammatory 
microenvironment to drive TEM by antigen-independent means. Further research 
is needed to determine the subset of genes that could be controlling autoreactive 
T cell trafficking. Identifying all of the key players involved would further the 
development of treatments in autoimmune diseases like multiple sclerosis, a 
pathology mediated by autoreactive T cell infiltration into tissues.  
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CHAPTER	V:	DISCUSSION	
  
 104 
Unraveling the complexities of TCR signaling mechanisms and how they 
drive T cell function is an area of considerable research in immunology. Highly 
dynamic T cell functions: clonal expansion, memory formation, metabolic 
reprogramming, and migration all depend on the quality of contact between the 
TCR and its cognate antigen. Here, we attempt to further understand how 
changes in TCR signaling effect the transcription of early response genes in 
CD8+ T cells, focusing on CD69, Nur77, CD25, and IRF4.  
We further explored the relationship between TCR signal strength and the 
Tec kinase ITK. A protein tyrosine kinase downstream of the TCR, ITK is unique 
in that it is not required for TCR signal transduction nor is it required for certain T 
cell functions. The Itk-/- mouse is able to mount an effective immune response to 
multiple pathogens including those that require a robust CD8+ T cell response, 
LCMV and Vaccinia virus, although with slower kinetics of clonal expansion 
(Atherly et al., 2006a). However, the knockout T cells are not completely normal 
and are defective in early calcium influx. Soon researchers discovered defects in 
CD4+ T cell function, specifically in TH9 and TH17 polarization and cytokine 
production (Gomez-Rodriguez et al., 2016; 2014). The transcription factor IRF4 
was a gene discovered to be sensitive to ITK activity and its function then linked 
to CD8+ T cell clonal expansion, with expression levels proportional to the 
magnitude of proliferation (Nayar et al., 2015; 2014; 2012). Here we describe a 
signaling mechanism connecting TCR signal strength and ITK activity to IRF4 
expression, a signaling process that was previously unknown.  
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Using the OT-I TCR transgenic model, we were able to carefully titrate 
both the dose and affinity of antigen and determine that some genes (e.g. Cd69 
and Nr4a1 (Nur77)) are mainly driven by antigen dose, while others, (e.g. Irf4 
and Il2ra (CD25)) are sensitive to both dose and affinity of the TCR:pMHC 
interaction. For example, cells stimulated with high doses of the low-affinity G4 
peptide were able to compensate for CD69 and Nur77 but were unable to 
produce the same levels of IRF4 and CD25 that their higher affinity N4 and T4 
clones could.  
We then explored the contribution of ITK on TCR signal strength using 
OT-I Itk-/- mice and the small molecule inhibitor PRN694. Similar to the effects 
seen with low affinity TCR activation, ITK inhibition specifically blunted the ability 
of the T cells to make maximum amounts of IRF4 and CD25. Similarly, CD69 and 
Nur77 were largely unaffected by the loss of ITK. Using the small molecules PMA 
and Ionomycin, we identified the calcium signaling pathway was a possible 
mediator of maximum IRF4 expression, because of the linear relationship 
observed between IRF4 expression and Ionomycin concentration.  
The calcium signaling pathway then lead us to focus on the calcium-
sensitive transcription factor NFAT and its likely relationship to IRF4 induction. 
Using a nuclear isolation assay adapted for flow cytometry, we discovered that 
NFAT activation was bimodal with the percentage of T cells with NFAT in the 
nucleus proportional to both dose and affinity of antigen. The all-or-nothing 
response was also sensitive to changes in ITK activity. However, this binary 
response to signaling was not similar to CD69 and Nur77. The maximum 
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percentage of cells with activated NFAT was driven by peptide affinity not dose. 
The percentage of activated NFAT was also sensitive to ITK activity, consistent 
with IRF4 data. By examining activated NFAT after the first hour of APC:T cell 
contact, we discovered that antigen affinity was also regulating the kinetics of 
NFAT activation. Even larger doses of the T4 peptide could not alter the time of 
activation. These findings led us to hypothesize that this delay in NFAT activation 
could explain the defect seen in IRF4 expression.  
To look at the early kinetics of IRF4 upregulation, we used a flow 
cytometry method of mRNA detection. An adaptation of fluorescence in situ 
hybridization techniques, these assays allowed us to examine Irf4 and Cd69 
mRNA transcription in early activated T cells stimulated with peptide-pulsed 
APCs. We modulated signal strength by inhibiting ITK. Consistent with the NFAT 
data, we found that the early kinetics of Irf4, and not Cd69, mRNA upregulation 
was sensitive to TCR signal strength. These kinetic findings allowed us to 
develop a model of IRF4 regulation where a delay in mRNA upregulation is 
driven by a delay in NFAT signaling. This delay is proportional to both antigen 
affinity and ITK activity and places the lower affinity clonal population at a 
disadvantage for IRF4 production.  
This handicap in IRF4 production is connected with the effector response 
of CD8+ T cells to infection (Nayar et al., 2015; 2014). We also examined the 
effect of TCR signal strength in the context of autoimmunity, specifically in the 
context of autoreactive T cell migration. We found that TCR signaling and CD28 
costimulation cooperated to regulate selectin binding, a critical early step in 
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transendothelial migration. This defect was mediated by ITK and correlated with 
the impaired ability of Itk-/- CD8+ T cells to lead to T cell-mediated pathology in an 
autoimmune adoptive transfer model. These data suggest that genes involved in 
migration, e.g. selectin binding, are also regulated by TCR signal strength. We 
posit that these genes are likely regulated by delayed mRNA kinetics in a similar 
manner as Irf4. In the following sections, we outline some of the caveats to these 
interpretations and propose additional experiments to address them. We suggest 
additional model systems to look at other T cell functions that could be 
modulated by these mechanisms. 
New	Insights	into	TCR	Signal	Strength	and	the	CD8+	T	Cell	Transcriptome	
Much of the research on graded TCR signaling regulation of the 
transcriptome has been done in CD4+ T cells. Antigen dose and affinity are 
known to have an effect on CD4+ T cell differentiation with dose linked to TH1 
over TH2 polarization (Constant 1995, Hosken 1995). Two recent papers have 
used different genomics techniques to look at changes in CD4+ T cell 
transcription in response to different strength TCR stimulation. Iwata et al. used 
varying doses of αCD3 stimulation in TH2 cells (Iwata et al., 2017). They were 
able to link BATF and IRF4 expression to antigen dose and then, performing 
BATF ChIP-Seq experiments, characterized distinct subsets of cells that were 
dependent on BATF-IRF4 and sensitive to the strength of TCR stimulation, 
expanding on previous work linking IRF4 and BATF to T cell transcription 
regulation (Kurachi et al., 2014). Going further, the authors then mapped 
enhancer regions of the genome that had varied occupancy of the BATF-IRF4 
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complex, discovering a new motif, AICE2, which was only bound in cells 
stimulated with high affinity antigen. This work suggested that graded IRF4 
expression levels in T cells could drive T cell function through altered binding 
dynamics to different enhancer regions, implying that enhancer regions with 
lower affinity for the BATF-IRF4 complex require maximum expression of the 
transcription factor for occupancy.  
Allison et al looked in AND CD4 TCR transgenic T cells stimulated with 
different doses and affinities of cognate peptides (Allison et al., 2016). They were 
then able to map areas of the genome that were sensitive to antigen dose and 
affinity, specifically areas that were enriched in histone acetylation, by performing 
H3K27Ac ChIP-Seq experiments. Consistent with our findings that Irf4 and Il2ra 
are highly sensitive to TCR signal strength, they found these genes highly 
enriched in enhancer elements. These regions also bound AP-1 and NF-κB 
further linking these pathways to the early response genes (Allison et al., 2016).  
Comprehensive genomic studies of CD8+ T cells involving graded TCR 
stimulation have recently been published (Richard et al., 2018). Here, Richard et 
al use the cutting-edge techniques of single-cell RNA sequencing (scRNA-seq) 
and mass cytometry (Using the CyTOF system) to look at changes in the 
transcriptome as well as proteome in activated OT-I T cells stimulated with 
different APLs. Using these single cell techniques, the authors added the 
dimension of time to their experiments and determined that graded TCR 
signaling drove the rate at which each cell initiated transcriptional activation, 
consistent with our observations with delayed NFAT and Irf4 mRNA activation. 
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However, this delay did not effect the cytolytic capacity of the activated CD8 T 
cells (Richard et al., 2018). We speculate that there could be a differential effect 
of genes acting on the fitness of the cell itself and those driving the fitness of the 
clonal population.  
These genomic studies have expanded our knowledge of TCR signaling 
dynamics and its modulation of transcription in T cells, further solidifying the role 
of IRF4 as an early response gene that is sensitive to changes in signal strength. 
We hypothesize that there are genes like Cd69 and Grzb that are not dependent 
on the kinetics of transcriptional activation while other genes like Irf4 and Il2ra 
may be more effected by the delay and in turn drive the diminished clonal 
expansion seen in vivo with low TCR stimulation. Using techniques used in these 
studies, it would be interesting to see which genes are sensitive to ITK inhibition, 
likely the genes most dependent on strong TCR stimulation. These techniques 
can also help to tease apart the contributions of transcriptional activation kinetics 
on the single T cell and the clonal population of T cells, identifying which genes 
are effected by the heterogeneity of signaling dynamics. This could then answer 
key questions regarding the transcriptional control of memory and effector 
differentiation in T cells, one model, which posits that TCR signal strength is the 
main driver of cells into the TEC pool. (Daniels and Teixeiro, 2015; Kaech and 
Cui, 2012) We hypothesize that there is a subset of migration genes that are also 
sensitive to TCR signal strength. Identification of this gene subset could be 
further researched using these genomics methods, specifically in the context of 
autoreactive T cells.   
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Looking	at	Graded	TCR	Signaling	Dynamics	In-Vivo	
Looking at signaling dynamics in vivo presents a variety of challenges due 
to the rapid dynamics of TCR signaling. While reporter mice like Nur77-GFP 
have proven quite useful, measuring the kinetics of activation can be difficult 
because of the stability of GFP. T cells that express the reporter have been 
activated through their TCR, however it is impossible to know how long the 
signaling event lasted, only that it happened. Researchers have recently 
described a new technology of reporter that can add this extra dimension of 
kinetic analysis. This new tool, a timer of cell kinetics and activity, or Tocky (Toki 
means time in Japanese) uses a unique genetically encoded fluorophore that 
changes fluorescence as the protein degrades (Subach et al., 2009). Briefly, 
these researchers identified mutants of mCherry that had different stability 
dynamics. One mutant first encodes a fluorophore molecule that emits 
fluorescence in the blue spectrum. Then, after ~7h, the protein conformation 
changed facilitating an oxidation reaction and double bond formation at the 
fluorescent site and the fluorophore then emitted in the red spectrum, now with 
increased stability and a decay half life of ~20h (Subach et al., 2009). In short, 
this reporter can identify cells that recently turned on the Tocky gene (Blue+), 
those that turned it on awhile ago (Red+), and those that are continuously 
transcribing the gene (Blue+ Red+).  
Bending et al did some elegant work using this technology to test new 
hypotheses in T cell biology (Bending et al., 2018). They made a reporter mouse 
by adding the Nr4a3 gene promoter to the Tocky construct and looked at T cell 
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activation in vivo. Nr4a3 is a relative of Nur77 and like its counterpart, is rapidly 
upregulated after TCR stimulation. Using Nr4a3-Tocky in OT-II cells as a proof of 
concept, they were able to capture the kinetics of the reporter with cells 
transitioning from blue to blue/red. Then with addition of anti-MHC II antibody to 
stop TCR signaling, the cells went from blue/red to just red. They then looked in 
thymic Treg precursors in these Nr4a3-Tocky mice at reporter expression in 7d 
neonates. Specifically, CD4SP thymocytes were gated on FoxP3+ and CD25+ 
expression. The FoxP3-CD25+ population was blue and the FoxP3+CD25+ 
population blue/red. The FoxP3+CD25- population had low reporter expression. 
This suggested that newly activated thymocytes turned on CD25 first and then 
persistent signaling lead to activation of FoxP3, with the FoxP3+CD25- population 
likely developing from weak TCR stimulation (Bending et al., 2018). 
These reporter mice can be used to study the kinetics of graded TCR 
signaling ex-vivo and in-vivo. It is unclear how long TCR signaling persists in the 
context of low to medium affinity interactions and how ITK activity controls this 
persistence. By looking at the Nr4a3-Tocky reporter in OT-I T cells under various 
signaling conditions, we can test the hypothesis that ITK is critical in maintaining 
durability of signal. The LmOVA strains can be used to test this time dependence 
in-vivo. Generation of an Irf4-Tocky mouse would be interesting to bridge the 
research contained in Chapter 3 with these new questions.  
A unique genetically encoded calcium biosensor has also been reported in 
T cells (Le Borgne et al., 2016). Using the mCameleon construct, a FRET based 
reporter that uses CFP-Calmodulin and YFP-M13 peptide, which binds itself 
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because of the calcium-dependent interaction between the protein and peptide, 
the authors looked at antigen avidity and calcium flux in single cells. They 
generated knockin mice with a Tet-inducible construct. They then tested it out in 
multiple TCR transgenic mice including OT-I. By looking at early naïve T cell 
interactions with APCs, they were able to measure the initial wave of calcium flux 
and characterized the amplitude and oscillation patterns. T cells were grouped by 
transient, sustained, and oscillating patterns. Interestingly, if you dilute the N4 
peptide, the majority of the responding T cells have a sustained calcium flux. 
Only the percentage of responding cells is diminished. When the dose is held 
constant and the affinity is changed by adding the Q4 and V4 APLs, the ratio of 
responders is the same. However, the number of cells with oscillating calcium 
flux is slightly increased. These experiments point to the all-or-nothing response 
of calcium flux triggering as sensitive to antigen dose, while the oscillation 
patterns are controlled by the affinity of the TCR:pMHC. Our hypothesis would be 
that graded TCR signaling and ITK activity would drive this shift from oscillation 
to sustained pattern. It is still unclear if sustained calcium oscillation drives 
nuclear NFAT activation. Using this reporter, you could test this by finding the 
dose of antigen, which gave predominately-oscillating cells, likely a low dose of 
low affinity peptide, and test the cells for nuclear NFAT. These oscillation 
patterns can then be linked to IRF4 upregulation by measuring Irf4 mRNA by 
flow.    
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Graded	TCR	Signaling	and	TCR	Repertoire	Diversity	
This work has focused on defining the signaling mechanism connecting graded 
TCR signaling, IRF4 expression, and CD8+ T effector cell expansion. We could 
use these methods to examine other aspects of T cell biology. One major 
hypothesis that has been under considerable investigation is that the strength of 
TCR signaling could be controlling the breadth of the TCR repertoire during 
infection, with high affinity interactions ensuring the greatest number of clones 
that survive and broadest spectrum of TCR sequences. Having a more diverse 
TCR repertoire, specifically in the memory pool, ensures that the organism can 
mount a robust recall response to reinfection with the same pathogen and 
possible mutant variants. This is usually best illustrated in the context of 
Influenza A infection where humans are yearly exposed to different variations of 
the virus. Indeed, the frequency of flu-specific CD8+ T cells was found to be 
protective against H1N1 during the 2009 pandemic, emphasizing the importance 
of CD8+ T cell memory in flu vaccination strategies (Sridhar et al., 2013).  
While there is evidence that the avidity of the TCR for antigen drives 
clonal diverisity in CD4+ and CD8+ T cells in multiple infection models (Busch and 
Pamer, 1999; Cukalac et al., 2014; McHeyzer-Williams et al., 1999; Price et al., 
2005), it remains unclear if ITK activity and IRF4 expression are driving repertoire 
diversity. This could be tested in WT, Itk-/-, Irf4+/fl, and Irf4fl/fl T cells. Different 
strategies could be used to look at repertoire diversity post-infection. In the 
Listeria monocytogenes model system you could use the APL variants (LmOVA) 
to look at how changes in TCR binding can alter clonal diversity and use the 
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variants to look at secondary reponses in the context of heterologous challenge 
(N4, T4, and V4) (Zehn et al., 2009).  
To look at small changes in TCR clonal diversity, WT, Itk-/-, Irf4+/fl, and 
Irf4fl/fl mice could be crossed onto a transgenic line (e.g. Vβ5) that holds constant 
the beta chain, narrowing the repertoire and allowing sequencing of the CDR3 
region of the alpha chain (Stadinski et al., 2011). Mice could be infected with 
LmOVA (N4, T4, and V4) strains followed by isolation of splenic T cells at the 
peak effector (D8) and memory (D45) time points. Then sorting of H2-Kb-
SIINFEKL (N4, T4, or V4) specific CD8+ T cells followed by single-cell deep 
sequencing of the TCRα CDR3 gene should measure changes in diversity when 
comparing WT, Itk-/-, Irf4+/fl, and Irf4fl/fl T cells. One caveat for the Itk-/- mice is the 
germline knockout, a Cre-inducible system would be preferred, allowing the T 
cells to exit the thymus normally without the skewed innate cell phenotype 
(Atherly et al., 2006b). The hypothesis would be that without strong TCR 
signaling (Itk-/-) and robust effector function (Irf4+/fl and Irf4fl/fl), the pathogen-
specific TCR repertoire would be narrower with only high affinity clones making 
up the effector and memory pools.   
NFAT-Independent	Regulation	of	IRF4	and	NF-κB	Signaling	
While NFAT is likely playing a critical role in IRF4 regulation in CD8+ T 
cells, it is not likely the only transcription factor that is driving early expression. 
The PMA dose response experiment (Figure 3.4) suggests a calcium 
independent factor that could be playing a role, possibly NF-κB. NF-κB is one of 
the three main signaling pathways downstream of the TCR that regulate gene 
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expression in early-activated T cells. Like other signaling pathways, co-
stimulation also plays a critical role with CD28 signaling driving PI3K activation, 
which recruits phosphoinositide-dependent kinase (PDK1) and AKT. Both PDK1 
and DAG can activate protein kinase C (PKCθ), the kinase that sets the NF-κB 
signaling pathway in motion after TCR stimulation (Lee et al., 2005; Park et al., 
2009).  
Briefly, the signaling cascade starts with PKCθ phosphorylating the CARD 
domain of CARMA1 causing a conformational change, allowing it to bind to 
BCL10 and MALT1. This three-protein complex (CBM) then recruits other factors, 
TRAF6 and MIB2, which facilitate the polyubiquitination of BCL10 and MALT1. 
This polyubiquitination motif then recruits the IκB kinase (IKK) complex, allowing 
for the ubiquitination of IKKγ followed by the phosphorylation of IKKβ. This newly 
activated IKKβ then critically phosphorylates Inhibitor of κB (IκBα) the factor that 
sequesters the NF-κB heterodimers (p65 and p50) in the cytoplasm. After 
phosphorylation, IκBα is ubiquitinated and degraded, allowing for the release of 
NF-κB to translocate to the nucleus and bind DNA. (Paul and Schaefer, 2013)  
While studies with αCD3 or TNFα stimulation of T cells suggest a digital 
regulation of the pathway, with the cell population shifting from p-IκBα negative to 
positive, clear data in the context of APC stimulated primary T cells is lacking 
(Kingeter et al., 2010; Tay et al., 2010). Further complicating the matter, there is 
much evidence that NF-κB regulation is also linked to calcium flux. Specifically, 
two calcium sensitive proteins, Calmodulin-dependent protein kinase (CaMKII) 
and the calcium dependent phosphatase Calcineurin, work to stabilize the 
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signaling cascade at the CBM complex with CaMKII phosphorylating CARMA 
and BCL10, and Calcineurin dephosphorylating other residues on BCL10, 
promoting complex stability and ubiquitination (Frischbutter et al., 2011; Ishiguro 
et al., 2007; Oruganti et al., 2011; Palkowitsch et al., 2011). The NF-κB family 
member c-Rel also binds to the Irf4 promoter, however, c-Rel is not highly 
expressed in naïve T cells and is also sensitive to calcium levels (Antonsson et 
al., 2003; Grumont and Gerondakis, 2000), another connection between the two 
pathways. The crosstalk between calcium signaling and NF-κB activation create 
the possibility that both signaling pathways control IRF4 expression. (Figure 5.1) 
We have some preliminary data suggesting an involvement of ITK in NF-
κB pathway control. (Appendix I) In OT-I T cells treated with PRN694, there is a 
reduction in BclXL expression, a pro-survival protein important for the clonal 
expansion of TECs. BclXL is known to be driven by p65 (C. Chen et al., 2000). 
We also looked at Irf4 mRNA expression in OT-I T cells treated with a small 
molecule inhibitor of NF-κB (BAY 11-7082) (Pierce et al., 1997). With pathway 
inhibition, there was also a delay in Irf4 mRNA kinetics, while not as potent as 
FK506. More studies are needed to explore the relationship between graded 
TCR signaling and NF-κB activation. Using the nuclear and RNA flow assays, the 
activation of nuclear p65 and upregulation of Bcl2l1 mRNA can be determined. 
These experiments would greatly add to our understanding of how the NF-κB 
pathway responds to graded TCR signaling in the context of TCR:pMHC 
stimulation.  
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Figure 5.1: Proposed model for NFAT and NF-κB dual control of early Irf4 
expression downstream of calcium signaling in activated T cells. 
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Figure 5.1: Proposed model for NFAT and NF-κB dual control of early Irf4 
expression downstream of calcium signaling in activated T cells. 
The rapid rise in intracellular calcium ion concentration activates the calcium 
sensitive protein Calmodulin, which can then activate the phosphatase 
Calcineurin as well as the kinase CaMKII. Calcineurin removes the inhibitory 
phosphorylation groups on NFAT in the cytoplasm allowing the transcription 
factor to translocate into the nucleus. Calcineurin and CaMKII can also both 
stabilize the CARMA1-BCL10-MALT1 complex, which is critical for NF-κB 
signaling. We propose that since both transcription factors are sensitive to 
calcium concentration that they both could be playing a role in IRF4 regulation.   
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Using	ITK	Mutants	to	Understand	ITK	Activation	and	Delay	of	Signaling	
While its biochemical function as a kinase has been known for some time 
(Berg et al., 2005), the roles of ITK’s multiple subdomains on its activation state 
and function have recently been examined more closely (Andreotti et al., 2018). 
The Tec family of kinases have not been crystallized in their full-length form. 
Researchers have instead crystallized different subdomains and have used 
homology models between Lck, BTK, and ITK to gain better insight into the 
structural basis for activation.  
ITK consists of 4 main protein regions: the pleckstrin homology-Tec 
homology (PHTH), SH3, SH2, and kinase domains. Insights into Lck structure 
have lead to a proposed autoinhibited conformation of ITK (Joseph et al., 2013; 
2007). In Lck, a tyrosine in the C-terminus (Y505) binds to its own SH2 domain, 
folding the protein together and masking the kinase domain activation loop. While 
ITK lacks this residue in its C-terminus, there is an acidic residue (E617) at the 
end of the kinase domain that can electrostatically interact with the basic residue 
(R265) in the SH2 domain, with mutants showing kinase activation (Joseph et al., 
2017). This interaction is weaker than the Y505 interaction in Lck suggesting that 
the autoinhibited form of ITK could more easily unravel with SH2 binding to other 
proteins. ITK is additionally kept in its inhibited folded state through interactions 
between the PHTH and kinase domains (Devkota et al., 2017; Joseph et al., 
2017). This inhibited state of ITK has more than one possible conformation with 
the weak inhibitory interactions and SH3 kinase linker binding to the PRR region 
promoting a less closed structure (Hao and August, 2002). (Figure 5.2A) 
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Multiple biochemical steps are required for the conformational change of 
ITK from its “closed” autoinhibited form and “open” activated form. One major 
interaction that is promoted by TCR and costimulatory signaling is the binding of 
the PHTH domain to PIP3 at the plasma membrane (Yang et al., 2001). The 
phospholipid PIP3 is the product of PI3K activity and is rapidly increased in 
concentration following T cell activation. Binding of the PHTH domain to PIP3 is 
crucial for two main reasons: it relieves the inhibitory interactions between it and 
the kinase domain and it colocalizes ITK to the plasma membrane, placing it in 
proximity to the LAT/SLP76 signaling complex (Devkota et al., 2017; Joseph et 
al., 2017). The SH3 domain can bind to SLP-76, anchoring ITK to the signaling 
complex and promoting a more open state (Bunnell et al., 2000; 1996). The SH2 
domain engages with the Y145 residue on SLP-76, releasing the autoinhibitory 
SH2-Kinase domain interaction. This then allows for autophosphorylation at Y180 
when the SH3 domain interacts with the kinase active site. (Figure 5.2A) 
Now that we know that ITK activity drives the kinetics of nuclear NFAT 
localization and Irf4 mRNA upregulation, we can use these signaling readouts in 
T cells to test the functionality of these regulatory domains of ITK. These flow 
cytometry methods are excellent for single-cell and single molecule studies. By  
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Figure 5.2: Proposed model of ITK activation states and key residues to 
target in mutagenesis experiments to look at single-molecule dynamics of 
ITK in the activated T cell. 
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Figure 5.2: Proposed model of ITK activation states and key residues to 
target in mutagenesis experiments to look at single-molecule dynamics of 
ITK in the activated T cell. 
(A) A model figure illustrating the autoinhibited conformation of ITK (on the left) 
and active conformation (on the right) as previously described  (Andreotti et al., 
2018). We propose experiments with mutants of the critical regulatory domain 
residues of ITK in primary T cells to study the molecular dynamics of the different 
conformation states in activated T cells, using single-cell methods. Key 
interacting residues are: E617 (Kinase domain) with R265 (SH2), Y180 (SH3) 
with SLP76, Y145 (SH2) with SLP76, K48 and R49 (PHTH) with Kinase domain, 
and KPLPPTP (Proline rich motif) with SH3.  
(B) Using single-cell methods detecting phosphorylation sites of ITK and its 
target PLCγ, we propose examining the dynamics of ITK conformational change 
in activated T cells over time. We propose that each cell has varying pools of the 
different active states of ITK and that it is not an all-or-nothing response as seen 
with other kinases (PKD2) (Navarro et al., 2014). The histograms represent 
possible signaling outcomes.  
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creating mutants of the key residues that control ITK conformation and function, 
we can better understand the structure-function relationship. (Figure 5.2B) Using 
CRISPR technology to knockin these ITK mutants in primary T cells, we can 
answer a significant question regarding ITK biology: Does graded TCR signaling 
effect the fraction of ITK molecules in the open active conformation? Its possible 
that there are a range of conformation states present in the cell. Developing 
antibodies against these different phospho-tyrosine residues would also be 
critical for addressing these questions. Navarro et al used similar methods using 
mutants and phospho-flo to study protein kinase D2 (PKD2) in single T cells, 
where they determined that the entire pool of PKD2 inside a single cell was 
activated upon TCR stimulation (Navarro et al., 2014). One hypothesis is that ITK 
would not follow this binary model, rather the proportion of the pool of ITK 
molecules inside the cell would shift to greater numbers in the open states. 
Likely, this shift would be dependent on TCR signal strength since we know that 
ITK activity is required during weak TCR stimulation. This hypothesis could be 
addressed using mutants and phospho-flo in the OT-I TCR transgenic model.  
This work can be further applied to study PLCγ activation. ITK 
phosphorylates PLCγ at Y783, however, the regulation of this process is highly 
complex and involves multiple protein-protein interactions at the LAT/SLP-76 
signaling complex. (Figure 5.3) The C-terminal SH2 domain (SH2C) of PLCγ is 
normally bound to the SH3 domain, masking the Y783 residue. Multiple 
interactions between PLCγ, ITK, and SLP-76 facilitate the active state where ITK  
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Figure 5.3: Proposed model of PLC-γ1 activation states and key residues to 
target in mutagenesis experiments to look at single-molecule dynamics of 
PLC-γ1 in the activated T cell. 
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Figure 5.3: Proposed model of PLC-γ1 activation states and key residues to 
target in mutagenesis experiments to look at single-molecule dynamics of 
PLC-γ1 in the activated T cell. 
A model figure illustrating the activation states of PLC-γ1 as previously described 
(Andreotti et al., 2018). We propose experiments with mutants of the critical 
regulatory domain residues of PLC-γ1 in primary T cells to study the molecular 
dynamics of the different conformation states in activated T cells, using single-
cell methods. Key interacting residues are: Y173 (SLP76) with SH2C of PLC-γ1 
and Y132 (LAT) with SH2N of PLC-γ1.    
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is able to phosphorylate Y783. The intramolecular pY783 and SH2C binding 
competes with the SLP-76 interaction with SH2C (Bunney et al., 2012; Devkota 
et al., 2015; Sela et al., 2011). (Figure 5.3) This can lead to the active enzyme 
falling off the LAT/SLP-76/ITK complex, creating room for another inactive 
molecule to take its place, amplifying the overall signal (Cruz-Orcutt et al., 2014; 
Devkota et al., 2015). It may be possible to use mutants of these different 
signaling molecules to study the effect of conformation states on TCR signal 
strength in primary T cells, using the OT-I model system and early NFAT 
activation or Irf4 mRNA upregulation as single-cell readouts.  
An additional level of proteasome-mediated PLCγ regulation was recently 
discovered. Cytokine-inducible SH2 containing protein (Cish), a member of the 
suppressor of cytokine signaling (SOCS) family, complexes with E3 ubiquitin 
ligase to target proteins for degradation. In T cells, Cish binds to PLCγ through its 
SH2 domain, facilitating PLCγ ubiquitination and degradation (Guittard et al., 
2018; Palmer et al., 2015). It would be interesting to look at changes in Cish 
expression in the OT-I model and see if sustained signaling drives down 
expression, leading to a greater pool of PLCγ available for signaling.  
Strategies	to	Determine	the	Mechanism	of	CD28/ITK	Control	of	Migration	
The insights that were learned in Chapter 4 are only a starting point for a more 
in-depth look at the coordination between CD28 and ITK leading to the regulation 
of TEM in T cells. Since there is good evidence that ITK controls P-selectin 
binding, one of the first steps would be to determine if this is done through PSGL-
1 or TIM-1. T cells from mice deficient in PSGL1 (Selplg-/-) or Tim-1 (Tim-1Δmucin) 
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could be treated with PRN694 and tested for P-selectin binding. These mice 
could also be crossed to Itk-/-. These T cells deficient in PSGL-1 or Tim-1 can 
also be tested in-vivo using the 2-photon imaging technique used on precision 
cut lung slices (PCLS). (Jain et al., 2013) ITK regulation of these genes could 
also be tested in OT-I T cells activated with peptide and treated with PRN694 
then stained for Selplg and Tim1 by RNA-flo. The kinetics of mRNA upregulation 
will be critical to test because that is the major defect observed with Irf4. Since 
ITK is more required in low affinity TCR stimulation, these experiments will have 
to be done with the T4 and G4 peptides.  
The RIP-mOVA / OT-I transfer model is also useful for testing a lot of 
these hypotheses. First, the RIP-mOVA mice can be crossed to B7-/- (Cd80-/- 
Cd86-/-) in order to confirm the CD28 dependence in this autoreactive T cell 
model. Since the Itk-deficient OT-Is showed a variable induction of T1D in the 
mice, a careful dose response of T4 peptide should be tested to confirm the 
threshold of TCR signaling that is required for migration of these autoreactive T 
cells to the pancreas. These experiments can also be done using the LmOVA-
SIITFEKL (T4) strain; testing the relationship between strength of TCR signaling 
on migration with or without an inflammatory environment. This model is highly 
adaptable and while it is non-physiological in its mechanism of T1D induction, it 
can be used to test small changes in TCR signaling on a relevant T cell function 
in-vivo.  
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Conclusions	
The relationship between the quality of antigen and the strength of the T 
cell response is a central topic of interest in immunology. Using a reductionist 
approach, we were able to describe a signaling mechanism for IRF4 expression 
in CD8+ T cells, which was driven by antigen dose and affinity as well as ITK 
activity. We further described a role of TCR signal strength on selectin binding 
and autoreactive T cell migration. We hypothesize that a subset of genes 
behaves in a similar way as IRF4. We also describe a critical function of ITK as 
an accelerator of signaling, explaining why it is important in some instances while 
not required for all T cell functions.  
Understanding how changes in TCR signaling effect changes in gene 
transcription allows us to ask additional questions related to T cell functions. One 
of these processes is the generation of optimal T cell memory, which is not 
completely understood and is a central paradigm in the adaptive immune 
response. Further research in this area will only improve vaccine development 
and T cell therapies.  
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Appendix	I	
ITK activity contributes to NF-κB pathway activation and the NF-κB 
pathway inhibitor inhibits Irf4 mRNA expression. 
Preliminary data in activated OT-I T cells shows that the NF-κB pathway could be 
playing a role in IRF4 regulation. In the first experiment, OT-I T cells were 
stimulated with the T4 peptide and stained for Bcl-xL expression after 24h. 
(Figure A.1A) We hypothesized that this survival protein, known for NF-κB 
dependence, specifically on RelA (p65) could be a good early response gene 
that is specifically dependent on the NF-κB pathway. We also tested the small 
molecule pathway inhibitor in the Irf4 mRNA experiments where OT-I T cells 
were stimulated with T4 peptide and stained for Irf4 mRNA early after activation. 
The inhibitor did delay the upregulation of the mRNA, consistent with the ITK 
inhibitor PRN694. (Figure A.1B) More studies are needed to determine the extent 
of NF-κB involvement on IRF4 expression. Specifically, we plan on using the 
nuclear flow cytometry method to look at early p65 activation in CD8+ T cells.   
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Figure A.1: Bcl-xL expression is sensitive to ITK activity in activated OT-I T 
cells; NF-κB pathway inhibitor (BAY 11-7082) delays Irf4 mRNA 
upregulation activated in OT-I T cells. 
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Figure A.1: Bcl-xL expression is sensitive to ITK activity in activated OT-I T 
cells; NF-κB pathway inhibitor (BAY 11-7082) delays Irf4 mRNA 
upregulation activated in OT-I T cells. 
(A) OT-I T cells were treated with 100nM T4 peptide for 24h either alone or in the 
presence of the ITK inhibitor PRN694 at doses of 200nM and 40nM. 
Representative histograms show Bcl-xL expression. 
(B) OT-I T cells were treated with 100nM T4 peptide for 2 and 6h either alone or 
in the presence of 100nM FK506 or 1µM BAY 11-7082. Representative 
histogram plots show Irf4 mRNA expression.  
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